var title_f11_16_11520="Chronic GVHD buccal mucosa";
var content_f11_16_11520=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oral chronic graft-versus-host disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Reticulated white plaques and erosions are present on the buccal mucosa. The findings resemble oral lichen planus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_16_11520=[""].join("\n");
var outline_f11_16_11520=null;
var title_f11_16_11521="Contents: Fluid and electrolytes";
var content_f11_16_11521=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/56/1934\">",
"       Endocrinology and Diabetes",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Fluid and electrolytes",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Fluid and electrolytes",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Drug effects",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/5/38998\">",
"           Amphotericin B nephrotoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/44/32451\">",
"           Complications of mannitol therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29094\">",
"           Diuretic-induced hyperuricemia and gout",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/39/19061\">",
"           Diuretics and calcium balance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/41/43668\">",
"           Diuretics and magnesium balance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/29/14806\">",
"           Ifosfamide nephrotoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/48/40710\">",
"           Loop diuretics: Maximum effective dose and major side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/13/39128\">",
"           Mechanism of action of diuretics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/43/42674\">",
"           NSAIDs and acetaminophen: Effects on blood pressure and hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/57/38803\">",
"           NSAIDs: Electrolyte complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/14/32999\">",
"           Renal toxicity of lithium",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/45/6868\">",
"           Time course of loop and thiazide diuretic-induced electrolyte complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/55/3962\">",
"           Use of diuretics in patients with heart failure",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Edematous states",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/36/34375\">",
"           Clinical manifestations and diagnosis of edema in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/50/30503\">",
"           General principles of the treatment of edema in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/12/17608\">",
"           Hyponatremia in patients with cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/53/38742\">",
"           Hyponatremia in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/31/20981\">",
"           Idiopathic edema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/44/19145\">",
"           Initial therapy of ascites in patients with cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/13/39128\">",
"           Mechanism of action of diuretics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/22/19818\">",
"           Natriuretic peptide measurement in heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/1/21527\">",
"           Pathogenesis of ascites in patients with cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/34/36393\">",
"           Pathophysiology and etiology of edema in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/40/35465\">",
"           Treatment of diuretic-resistant ascites in patients with cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/40/650\">",
"           Treatment of refractory edema in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Endocrine disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/46/28391\">",
"           Adrenal steroid biosynthesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/56/40838\">",
"           Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/1/37911\">",
"           Clinical features of primary aldosteronism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/32/15878\">",
"           Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/44/9930\">",
"           Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/5/22615\">",
"           Familial hyperaldosteronism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/16/40199\">",
"           Treatment of primary aldosteronism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/51/35641\">",
"           Uncommon causes of congenital adrenal hyperplasia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hypercalcemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/28/20934\">",
"           Diagnostic approach to hypercalcemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/51/19258\">",
"           Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/22/28007\">",
"           Etiology of hypercalcemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/8/23685\">",
"           Relation between total and ionized serum calcium concentration",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/42/16041\">",
"           Treatment of hypercalcemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hyperkalemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/5/33882\">",
"           Causes and evaluation of hyperkalemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/2/44069\">",
"           Clinical manifestations of hyperkalemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/44/9930\">",
"           Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/17/25876\">",
"           Hyponatremia and hyperkalemia in adrenal insufficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/18/25891\">",
"           Potassium balance in acid-base disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/53/10069\">",
"           Renal effects of ACE inhibitors in heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/54/17258\">",
"           Treatment and prevention of hyperkalemia in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hypermagnesemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/58/13220\">",
"           Causes and treatment of hypermagnesemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/29/470\">",
"           Regulation of magnesium balance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/9/32914\">",
"           Symptoms of hypermagnesemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hypernatremia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/63/36857\">",
"           Etiology and evaluation of hypernatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/48/11018\">",
"           General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/58/23464\">",
"           Manifestations of hyponatremia and hypernatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/52/24393\">",
"           Treatment of hypernatremia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hyperphosphatemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/13/13527\">",
"           Overview of the causes and treatment of hyperphosphatemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/57/33690\">",
"           Treatment of hyperphosphatemia in chronic kidney disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hypocalcemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/13/34005\">",
"           Diagnostic approach to hypocalcemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/51/19258\">",
"           Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/25/24984\">",
"           Etiology of hypocalcemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/8/23685\">",
"           Relation between total and ionized serum calcium concentration",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/37/44632\">",
"           Treatment of hypocalcemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hypokalemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/56/40838\">",
"           Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/13/5338\">",
"           Approach to the patient with hypertension and hypokalemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/43/23226\">",
"           Bartter and Gitelman syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/17/5402\">",
"           Causes of hypokalemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/1/37911\">",
"           Clinical features of primary aldosteronism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/2/9258\">",
"           Clinical manifestations and treatment of hypokalemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/9/9366\">",
"           Evaluation of the patient with hypokalemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/5/22615\">",
"           Familial hyperaldosteronism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/51/25399\">",
"           Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/54/871\">",
"           Hyperkalemic periodic paralysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/6/6245\">",
"           Hypokalemia-induced renal dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/62/9193\">",
"           Hypokalemic periodic paralysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/18/25891\">",
"           Potassium balance in acid-base disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/16/40199\">",
"           Treatment of primary aldosteronism",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hypomagnesemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/41/15000\">",
"           Causes of hypomagnesemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/63/11254\">",
"           Evaluation and treatment of hypomagnesemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/29/470\">",
"           Regulation of magnesium balance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/45/16085\">",
"           Significance of hypomagnesemia in cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/37/42580\">",
"           Signs and symptoms of magnesium depletion",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hyponatremia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/30/3562\">",
"           Causes of hyponatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/23/8567\">",
"           Cerebral salt-wasting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/31/502\">",
"           Diuretic-induced hyponatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/23/38260\">",
"           Estimation of the sodium deficit in patients with hyponatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/20/21832\">",
"           Evaluation of the patient with hyponatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/42/1706\">",
"           Exercise-associated hyponatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/17/25876\">",
"           Hyponatremia and hyperkalemia in adrenal insufficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/41/8858\">",
"           Hyponatremia following transurethral resection or hysteroscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/12/17608\">",
"           Hyponatremia in patients with cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/53/38742\">",
"           Hyponatremia in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/58/23464\">",
"           Manifestations of hyponatremia and hypernatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/53/10074\">",
"           Osmotic demyelination syndrome and overly rapid correction of hyponatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/34/18986\">",
"           Overview of the treatment of hyponatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/46/7913\">",
"           Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/57/17306\">",
"           Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hypophosphatemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/25/15767\">",
"           Causes of hypophosphatemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/7/2167\">",
"           Diagnosis and treatment of hypophosphatemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/42/28324\">",
"           Hypophosphatemia in the alcoholic patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/29/14806\">",
"           Ifosfamide nephrotoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/57/32659\">",
"           Signs and symptoms of hypophosphatemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Issues in diabetes mellitus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/55/4986\">",
"           Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/16/44295\">",
"           Epidemiology and pathogenesis of diabetic ketoacidosis and hyperosmolar hyperglycemic state",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/7/34935\">",
"           Maintenance and replacement fluid therapy in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/48/15114\">",
"           Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Metabolic acidosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/57/29589\">",
"           Acid-base and electrolyte abnormalities with diarrhea or ureteral diversion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/29/6613\">",
"           Alcoholic and fasting ketoacidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/44/31432\">",
"           Approach to the adult with metabolic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/44/40646\">",
"           Bicarbonate therapy in lactic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/44/3781\">",
"           Causes of lactic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/55/4986\">",
"           Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/18/18723\">",
"           D-Lactic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/16/44295\">",
"           Epidemiology and pathogenesis of diabetic ketoacidosis and hyperosmolar hyperglycemic state",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/44/18120\">",
"           Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/29/14806\">",
"           Ifosfamide nephrotoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/3/4154\">",
"           Methanol and ethylene glycol poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/26/23973\">",
"           Nephrolithiasis in renal tubular acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/32/10759\">",
"           Overview of renal tubular acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/24/41353\">",
"           Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/13/19672\">",
"           Pathophysiology of renal tubular acidosis and the effect on potassium balance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/18/25891\">",
"           Potassium balance in acid-base disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/43/36533\">",
"           Serum anion gap in conditions other than metabolic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/41/27288\">",
"           Simple and mixed acid-base disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/61/20437\">",
"           Strong ions and the analysis of acid-base disturbances (Stewart approach)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/1/21526\">",
"           The ������anion gap/������HCO3 ratio in patients with a high anion gap metabolic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/48/15114\">",
"           Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/46/5860\">",
"           Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/18/11558\">",
"           Urine anion and osmolal gaps in metabolic acidosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Metabolic alkalosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/56/40838\">",
"           Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/43/23226\">",
"           Bartter and Gitelman syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/22/8551\">",
"           Causes of metabolic alkalosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/35/39479\">",
"           Clinical manifestations and evaluation of metabolic alkalosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/51/25399\">",
"           Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/28/10692\">",
"           Pathogenesis of metabolic alkalosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/41/27288\">",
"           Simple and mixed acid-base disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/14/14568\">",
"           Treatment of metabolic alkalosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/16/40199\">",
"           Treatment of primary aldosteronism",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/46/28391\">",
"           Adrenal steroid biosynthesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/45/36570\">",
"           Assessment of kidney function",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/23/35190\">",
"           Calculation of the creatinine clearance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/57/41875\">",
"           Drugs that elevate the serum creatinine concentration",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/26/39332\">",
"           Electrolyte disturbances with HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/56/24457\">",
"           Etiology, clinical manifestations, and diagnosis of volume depletion in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/50/29482\">",
"           Hepatorenal syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/0/7177\">",
"           Hypouricemia: Causes and clinical significance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/60/20423\">",
"           Isopropyl alcohol poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/7/34935\">",
"           Maintenance and replacement fluid therapy in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/22/19818\">",
"           Natriuretic peptide measurement in heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/61/24533\">",
"           Nitric oxide and the kidney",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/0/41988\">",
"           Reciprocal serum creatinine concentration and chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/25/44435\">",
"           Renal actions of dopamine",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/53/10069\">",
"           Renal effects of ACE inhibitors in heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/29/41430\">",
"           Serum osmolal gap",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/20/13639\">",
"           Treatment of severe hypovolemia or hypovolemic shock in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Polyuria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/35/21048\">",
"           Clinical manifestations and causes of central diabetes insipidus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/2/21545\">",
"           Clinical manifestations and causes of nephrogenic diabetes insipidus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/47/24312\">",
"           Diagnosis of polyuria and diabetes insipidus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/14/32999\">",
"           Renal toxicity of lithium",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/31/505\">",
"           Treatment of central diabetes insipidus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/32/24071\">",
"           Treatment of nephrogenic diabetes insipidus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/34/6691\">",
"           Urine output in diabetes insipidus",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-A9D826A122-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f11_16_11521=[""].join("\n");
var outline_f11_16_11521=null;
var title_f11_16_11522="Patient information: Cauda equina syndrome (The Basics)";
var content_f11_16_11522=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/84039\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/0/7171\">",
"         Cauda equina syndrome",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/51/4917\">",
"          Anatomy of the back",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?40/62/41954\">",
"         Patient information: Herniated disc (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/7/36978\">",
"         Patient information: Low back pain in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/44/40642\">",
"         Patient information: Spinal stenosis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?8/47/8950\">",
"         Patient information: Low back pain in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Cauda equina syndrome (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/cauda-equina-syndrome-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H180778907\">",
"      <span class=\"h1\">",
"       What is the cauda equina?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The cauda equina is a bundle of nerves that spread out from the bottom of the spinal cord (",
"      <a class=\"graphic graphic_figure graphicRef83945 \" href=\"UTD.htm?7/0/7171\">",
"       figure 1",
"      </a>",
"      ). The spinal cord is the highway of nerves that runs from the base of the brain all the way down the back.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H180778939\">",
"      <span class=\"h1\">",
"       What is cauda equina syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cauda equina syndrome is the medical term for a group of symptoms that happen when some of the nerves in the cauda equina get squeezed or damaged. The symptoms of cauda equina syndrome include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain, numbness, or tingling in the low back and spreading down 1 or both legs",
"       </li>",
"       <li>",
"        Leg weakness or a problem called &ldquo;foot drop,&rdquo; which is when you cannot seem to hold your foot up (for example, while walking)",
"       </li>",
"       <li>",
"        Problems with bowel or bladder control",
"       </li>",
"       <li>",
"        Problems with sex",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H180778954\">",
"      <span class=\"h1\">",
"       What causes cauda equina syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To understand the causes of cauda equina syndrome, it&rsquo;s helpful to first learn a little about the back and spine.",
"     </p>",
"     <p>",
"      The back is made up of (",
"      <a class=\"graphic graphic_figure graphicRef56246 \" href=\"UTD.htm?4/51/4917\">",
"       figure 2",
"      </a>",
"      ):",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Vertebrae &ndash; A stack of bones that sit on top of 1 another like a stack of coins. Each of these bones has a hole in the center. When stacked, the bones form a hollow tube that protects the spinal cord.",
"       </li>",
"       <li>",
"        Spinal cord and nerves &ndash; The spinal cord runs through the vertebrae. Nerves branch from the spinal cord and pass in between the vertebrae. From there they connect to the arms, the legs, and the organs. (This is why problems in the back can cause leg pain or bladder problems.)",
"       </li>",
"       <li>",
"        Discs &ndash; Rubbery discs sit in between each of the vertebrae to add cushion and allow movement. The discs that sit between the vertebrae have a tough outer shell and jelly-like center. The outer shell of the discs can sometimes break open, spilling the jelly material inside. This is what doctors call a &ldquo;herniated disc.&rdquo;",
"       </li>",
"       <li>",
"        Muscles, tendons, and ligaments &ndash; Together the muscles, tendons, and ligaments are called the \"soft tissues\" of the back. These soft tissues support the back and help hold it together.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Cauda equina syndrome can happen because of changes in the back that affect the nerves. For example, cauda equina syndrome can happen because of:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A herniated disc &ndash; The material from a ruptured disc can press on or irritate the nerves in the cauda equina.",
"       </li>",
"       <li>",
"        Infection or inflammation &ndash; Many different types of infection can damage or irritate nerves in the cauda equina.",
"       </li>",
"       <li>",
"        Cancer &ndash; In people with cancer, tumors can form within the spine and press on the nerves in the cauda equina.",
"       </li>",
"       <li>",
"        Spinal stenosis &ndash; Spinal stenosis is a condition in which the vertebrae form bumps called bone spurs. These bumps can squeeze or press on the nerves in the cauda equina. In people with spinal stenosis, the discs between the vertebrae also tend to dry up and shrink. That causes the space between the vertebrae to get smaller, sometimes pinching nerves.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H180778986\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, if you have symptoms of cauda equina syndrome, see a doctor or nurse right away. Cauda equina syndrome is a medical emergency.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H180779001\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will need to find out what is causing your symptoms. You will likely have an MRI. This is an imaging test that can create detailed pictures of the spinal cord and nearby tissues.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H180779016\">",
"      <span class=\"h1\">",
"       How is cauda equina syndrome treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment for cauda equina syndrome involves removing whatever is pressing on the nerves and causing the symptoms. Often that means having surgery to remove bits of bone or discs, or tumors. If the cause of the cauda equina syndrome is a tumor, radiation to shrink the tumor might also be an option.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H180779031\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/7/36978?source=see_link\">",
"       Patient information: Low back pain in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/62/41954?source=see_link\">",
"       Patient information: Herniated disc (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/44/40642?source=see_link\">",
"       Patient information: Spinal stenosis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/47/8950?source=see_link\">",
"       Patient information: Low back pain in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?11/16/11522?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 84039 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-8DAC4F1F78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_16_11522=[""].join("\n");
var outline_f11_16_11522=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H180778907\">",
"      What is the cauda equina?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H180778939\">",
"      What is cauda equina syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H180778954\">",
"      What causes cauda equina syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H180778986\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H180779001\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H180779016\">",
"      How is cauda equina syndrome treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H180779031\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/84039\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/0/7171\">",
"      Cauda equina syndrome",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/51/4917\">",
"       Anatomy of the back",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/62/41954?source=related_link\">",
"      Patient information: Herniated disc (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/47/8950?source=related_link\">",
"      Patient information: Low back pain in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/7/36978?source=related_link\">",
"      Patient information: Low back pain in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/44/40642?source=related_link\">",
"      Patient information: Spinal stenosis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_16_11523="Patient information: Infertility in women (The Basics)";
var content_f11_16_11523=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15424\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"         Female reproductive anatomy",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/50/3876\">",
"          How pregnancy happens",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?6/25/6547\">",
"         Patient information: Infertility in couples (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/42/40610\">",
"         Patient information: Infertility in men (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?25/63/26611\">",
"         Patient information: Endometriosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/42/22180\">",
"         Patient information: Evaluation of the infertile couple (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/62/40932\">",
"         Patient information: In vitro fertilization (IVF) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/14/10468\">",
"         Patient information: Infertility treatment with gonadotropins (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/4/34883\">",
"         Patient information: Ovulation induction with clomiphene (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/5/32851\">",
"         Patient information: Treatment of male infertility (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Infertility in women (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/infertility-in-women-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H458566952\">",
"      <span class=\"h1\">",
"       What are the reasons a woman might have trouble getting pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A woman can have trouble getting pregnant for different reasons. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Problems with ovulation &ndash; Ovulation is the time in a woman&rsquo;s monthly cycle when the ovary releases an egg into the fallopian tube (",
"        <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"         figure 1",
"        </a>",
"        and",
"        <a class=\"graphic graphic_figure graphicRef73238 \" href=\"UTD.htm?3/50/3876\">",
"         figure 2",
"        </a>",
"        ). Hormones control ovulation. Pregnancy can occur if sperm fertilizes the egg as it travels to the uterus after ovulation. Women have the highest chance of getting pregnant if they have sex 1 to 2 days before ovulation or on the day of ovulation. In some women, ovulation does not happen on a regular basis or at all.",
"       </li>",
"       <li>",
"        Problems with the uterus or fallopian tubes &ndash; For example, some women have scar tissue in their fallopian tubes from past infections or surgery. This scar tissue can cause the fallopian tubes to be blocked.",
"       </li>",
"       <li>",
"        Endometriosis &ndash; Endometriosis is a condition that can cause pain in the lower part of the belly. This can also lead to trouble getting pregnant.",
"       </li>",
"       <li>",
"        Older age &ndash; Once women get into their mid-to-late 30s, it can be harder to get pregnant, so it can take longer. Getting pregnant can be even more of a problem for women in their 40s.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H458566959\">",
"      <span class=\"h1\">",
"       When should I see a doctor?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor if you do not get pregnant after having unprotected sex for one year. But if you get worried before then, see your doctor sooner. And if you are older than 35, see your doctor if you can&rsquo;t get pregnant after 6 months of trying.",
"     </p>",
"     <p>",
"      Your doctor will talk with you and do an exam. He or she will often do tests to try to figure out the cause of the problem. Plus, your partner might need to be tested, too. But don&rsquo;t be surprised if your doctor cannot tell you what is wrong. It&rsquo;s not always possible to find out why a woman cannot get pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H458566966\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are overweight, losing weight might help you become pregnant. Losing weight can also help you have a healthier pregnancy when you become pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H458566973\">",
"      <span class=\"h1\">",
"       What treatments are available?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Women who have trouble getting pregnant might choose to have one or more of the following treatments. You and your doctor should discuss which treatment to try first. Treatments can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A medicine called",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?17/14/17636?source=see_link\">",
"         clomiphene",
"        </a>",
"        (sold as Clomid&reg; or Serophene&reg;) &ndash; This medicine improves the chances that ovulation will occur. Many times, doctors prescribe this treatment first. Your doctor will tell you how and when to take this medicine. He or she will also tell you when to have sex so the treatment has the best chance of working. If this medicine does not work after a few months, your doctor might recommend trying other medicines to help with ovulation.",
"       </li>",
"       <li>",
"        Hormone shots &ndash; Hormone shots are often recommended if a woman does not get pregnant with",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?17/14/17636?source=see_link\">",
"         clomiphene",
"        </a>",
"        . Hormones improve the chances that ovulation will occur. Your doctor will tell you how and when to do this treatment.",
"       </li>",
"       <li>",
"        Intrauterine insemination &ndash; For this treatment, a doctor uses a tube to place sperm directly inside a woman&rsquo;s uterus. This is done right before ovulation. Some women have this treatment along with hormone shots.",
"       </li>",
"       <li>",
"        In vitro fertilization, also called &ldquo;IVF&rdquo; &ndash; IVF is a procedure that is usually done if other treatments have not worked. It involves the following:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        A woman gives herself hormone shots for a few weeks. These hormones get the ovary ready to ovulate.",
"       </li>",
"       <li>",
"        Just before ovulation, the doctor uses a thin needle to remove some eggs from the ovaries. He or she does this through the vagina.",
"       </li>",
"       <li>",
"        The eggs are put into a test tube with sperm so that the sperm can fertilize 1 or more eggs.",
"       </li>",
"       <li>",
"        After 2 to 5 days, the fertilized egg or eggs are put in the woman&rsquo;s uterus. &nbsp;Hopefully, one of the eggs will attach to the uterus and grow into a pregnancy.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        IVF is usually done in women:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Whose fallopian tubes are missing or blocked",
"       </li>",
"       <li>",
"        With male partners who have too few sperm",
"       </li>",
"       <li>",
"        Who have not been able to get pregnant using other treatments",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H458566980\">",
"      <span class=\"h1\">",
"       How will I know if a treatment is working?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor will do tests at different times during treatment to check if it is working. These tests can include blood tests and ultrasound. Ultrasound is an imaging test that creates pictures of the inside of the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H458566987\">",
"      <span class=\"h1\">",
"       Do treatments always work?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. Treatments do not always help a woman get pregnant. The same treatment can work for one woman, but not another.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H458566994\">",
"      <span class=\"h1\">",
"       How do I decide which treatment to have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Talk with your doctor about the benefits and downsides of the different treatments. To choose the treatment that is right for you, you might want to think about:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        How well your doctor thinks the treatment will work",
"       </li>",
"       <li>",
"        Cost of the treatment &ndash; Some treatments cost a lot of money. Health insurance does not pay for all types of treatments.",
"       </li>",
"       <li>",
"        How long the treatment will take &ndash; Treatments might need to be done more than once to work. Getting pregnant can take months to years.",
"       </li>",
"       <li>",
"        Side effects and downsides of the treatment",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You should also talk with your doctor about other options for having children, such as adoption.",
"     </p>",
"     <p>",
"      A woman can have a tough time making these decisions. You might find it helpful to talk to a counselor or go to a support group for people who are having trouble getting pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H458567001\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/25/6547?source=see_link\">",
"       Patient information: Infertility in couples (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/42/40610?source=see_link\">",
"       Patient information: Infertility in men (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34883?source=see_link\">",
"       Patient information: Ovulation induction with clomiphene (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/14/10468?source=see_link\">",
"       Patient information: Infertility treatment with gonadotropins (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/62/40932?source=see_link\">",
"       Patient information: In vitro fertilization (IVF) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/42/22180?source=see_link\">",
"       Patient information: Evaluation of the infertile couple (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/5/32851?source=see_link\">",
"       Patient information: Treatment of male infertility (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/63/26611?source=see_link\">",
"       Patient information: Endometriosis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?11/16/11523?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15424 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-9C35C7E240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_16_11523=[""].join("\n");
var outline_f11_16_11523=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H458566952\">",
"      What are the reasons a woman might have trouble getting pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H458566959\">",
"      When should I see a doctor?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H458566966\">",
"      Is there anything I can do on my own?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H458566973\">",
"      What treatments are available?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H458566980\">",
"      How will I know if a treatment is working?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H458566987\">",
"      Do treatments always work?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H458566994\">",
"      How do I decide which treatment to have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H458567001\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15424\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"      Female reproductive anatomy",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/50/3876\">",
"       How pregnancy happens",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/63/26611?source=related_link\">",
"      Patient information: Endometriosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/42/22180?source=related_link\">",
"      Patient information: Evaluation of the infertile couple (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/62/40932?source=related_link\">",
"      Patient information: In vitro fertilization (IVF) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/25/6547?source=related_link\">",
"      Patient information: Infertility in couples (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/42/40610?source=related_link\">",
"      Patient information: Infertility in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/14/10468?source=related_link\">",
"      Patient information: Infertility treatment with gonadotropins (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34883?source=related_link\">",
"      Patient information: Ovulation induction with clomiphene (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/5/32851?source=related_link\">",
"      Patient information: Treatment of male infertility (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_16_11524="Lap hernia still B";
var content_f11_16_11524=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F77859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F77859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lap hernia still B",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 416px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_16_11524=[""].join("\n");
var outline_f11_16_11524=null;
var title_f11_16_11525="Diameters fetal head";
var content_f11_16_11525=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 549px\">",
"   <div class=\"ttl\">",
"    Diameters of the fetal head at term",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 529px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pritchard, JA, MacDonald, PC. Williams Obstetrics, 16th Edition, Appleton-Century-Crofts, New York 1980. Copyright &copy;1980 McGraw Hill. p.177.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_16_11525=[""].join("\n");
var outline_f11_16_11525=null;
var title_f11_16_11526="Peripheral blood B cell ALL";
var content_f11_16_11526=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F83240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F83240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Peripheral blood smear of acute lymphoblastic leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 424px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral blood smear shows small, uniform blasts with scant cytoplasm and inconspicuous nucleoli (L1 morphology). Wright-Giemsa, 100x magnification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sun T. Clinical application. In: Flow Cytometry, Immunochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_16_11526=[""].join("\n");
var outline_f11_16_11526=null;
var title_f11_16_11527="Ado-trastuzumab emtansine: Drug information";
var content_f11_16_11527=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ado-trastuzumab emtansine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/41/9877?source=see_link\">",
"    see \"Ado-trastuzumab emtansine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F16248342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F16253283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kadcyla&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F16248345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Anti-HER2;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Antimicrotubular;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Monoclonal Antibody",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F16255288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Do not substitute ado-trastuzumab for or with conventional trastuzumab; products are different and are",
"     <b>",
"      NOT",
"     </b>",
"     interchangeable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Breast cancer, metastatic, HER2+:",
"     </b>",
"     I.V.: 3.6 mg/kg every 3 weeks until disease progression or unacceptable toxicity; Maximum dose: 3.6 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Missed doses:",
"     </i>",
"     If a planned dose is missed or delayed, administer as soon as possible (at the dose and rate most recently tolerated), do not wait until the next planned cycle. Then adjust schedule to maintain a 3-week interval between doses.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F16255289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16255291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16255292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F16255290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     After a dose reduction is implemented, do not re-escalate dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Infusion-related reaction:",
"     </i>",
"     Slow infusion rate or interrupt infusion. Permanently discontinue if life-threatening infusion reactions occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Dose levels for dosage reductions and/or discontinuation:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Starting dose: 3.6 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     First dose reduction: Reduce dose to 3 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Second dose reduction: Reduce dose to 2.4 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Further reductions necessary: Discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Hematologic toxicity:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Grade 3 thrombocytopenia (platelets 25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     to &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ): Withhold treatment until platelet count recovers to &le; grade 1 (platelets &ge;75,000/mm3), then resume treatment at the same dose level.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Grade 4 thrombocytopenia (platelets &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ): Withhold treatment until platelet count recovers to &le; grade 1 (platelets &ge;75,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ), then resume treatment with one dose level reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Cardiotoxicity:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     LVEF &gt;45%: Continue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     LVEF 40% to &le;45% and decrease is &lt;10% points from baseline: Continue treatment and repeat LVEF assessment within 3 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     LVEF 40% to &le;45% and decrease is &ge;10% points from baseline: Withhold treatment and repeat LVEF assessment within 3 weeks; if repeat LVEF has not recovered to within 10% points from baseline, discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     LVEF &lt;40%: Withhold treatment and repeat LVEF assessment within 3 weeks; if repeat LVEF is confirmed &lt;40%, discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     HF (symptomatic): Discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Hepatotoxicity:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Grade 2 ALT, AST elevations (&gt;2.5 to &le;5 times ULN): Continue at same dose level.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Grade 3 ALT, AST elevations (&gt;5 to &le;20 times ULN): Withhold until ALT, AST recover to &le; grade 2, then resume with one dose level reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Grade 4 ALT, AST elevations (&gt;20 times ULN): Permanently discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Grade 2 hyperbilirubinemia (&gt;1.5 to &le;3 times ULN): Withhold until bilirubin recovers to &le; grade 1 (&le;1.5 times ULN), then resume at the same dose level.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Grade 3 hyperbilirubinemia (&gt;3 to &le;10 times ULN): Withhold until bilirubin recovers to &le; grade 1, then resume with one dose level reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Grade 4 hyperbilirubinemia (&gt;10 times ULN): Permanently discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Concomitant ALT, AST &gt;3 times ULN and total bilirubin &gt;2 times ULN: Permanently discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Nodular regenerative hyperplasia: Permanently discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Peripheral neuropathy, grade 3 or 4:",
"     </i>",
"     Temporarily discontinue until resolves to &le; grade 2.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Pulmonary toxicity:",
"     </i>",
"     Interstitial lung disease or pneumonitis: Permanently discontinue.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F16253284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kadcyla&trade;: 100 mg, 160 mg [contains sucrose 6% w/v; derived from or manufactured using Chinese hamster ovary cells]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F16255120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F16255361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Check label to ensure appropriate product is being administered (ado-trastuzumab emtansine and conventional trastuzumab are different products and are",
"     <b>",
"      NOT",
"     </b>",
"     interchangeable).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Infuse over 90 minutes (first infusion) or over 30 minutes (subsequent infusions if prior infusions were well tolerated) through a 0.22 micron inline nonprotein adsorptive polyethersulfone filter. Do not administer I.V. push or bolus. Do not administer with other medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Closely monitor infusion site during administration. Monitor patient during infusion for signs of infusion-related reactions (eg, fever, chills); monitor for at least 90 minutes following initial infusion and (if tolerated) for at least 30 minutes following subsequent infusions.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F16255181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS;",
"     <b>",
"      incompatible",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F16248201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HER2-positive, metastatic breast cancer in patients who previously received trastuzumab and a taxane, separately or in combination, and have either received prior therapy for metastatic disease or developed disease recurrence during or within 6 months of completing adjuvant therapy.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F16255118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ado-trastuzumab emtansine may be confused with trastuzumab",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ado-trastuzumab emtansine (Kadcyla&trade;) may be confused with conventional trastuzumab (Herceptin&reg;); products are",
"       <b>",
"        not",
"       </b>",
"       interchangeable.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F16330709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (36%), headache (28%), fever (19%), insomnia (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Skin rash (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (40%), constipation (27%), diarrhea (24%), abdominal pain (19%), vomiting (19%), xerostomia (17%), stomatitis (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Thrombocytopenia (31%; grades 3/4: 15%; Asians grades 3/4: 45%), anemia (14%; grades 3/4: 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Increased serum aspartate aminotransferase (98%; grades 3/4: &lt;8%), increased serum alanine aminotransferase (82%; grades 3/4: &lt;6%), increased serum transaminases (29%), increased serum bilirubin (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Musculoskeletal pain (36%), peripheral neuropathy (21%; grades 3/4: 2%), arthralgia (19%), weakness (18%), myalgia (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Epistaxis (23%), cough (18%), dyspnea (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (7%), hypertension (5%; grades 3/4: 1%), left ventricular systolic dysfunction (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (10%), chills (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypokalemia (10%; grades 3/4: 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Dyspepsia (9%), dysgeusia (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary:	Urinary tract infection (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Neutropenia (7%; grades 3/4: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Increased serum alkaline phosphatase (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Infusion related reaction (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Blurred vision (5%), conjunctivitis (4%), dry eye syndrome (4%), lacrimation (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Pneumonitis (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Antibody development (5%), hypersensitivity (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, hepatic encephalopathy, hepatic nodular regenerative hyperplasia, hepatotoxicity, portal hypertension",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F16255125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F16255126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bone marrow suppression: Thrombocytopenia may occur. The incidence of thrombocytopenia may be higher in patients of Asian ancestry. Monitor platelet count at baseline and prior to each dose. May require treatment interruption or dose reduction. Monitor closely if at bleeding risk due to thrombocytopenia and/or concomitant anticoagulant use. Neutropenia and anemia have also occurred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: May result in left ventricular ejection fraction (LVEF) reductions. Evaluate left ventricular function (in all patients) prior to and at least every 3 months during treatment; withhold for clinically significant left ventricular function decreases.",
"     </b>",
"     Treatment interruption or dosage reductions are required inpatients who develop LVEF declines. Use has not been studied in patients with LVEF &lt;50% at baseline, with symptomatic CHF, serious arrhythmia, or recent history (within 6 months) of MI, or unstable angina.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Extravasation reactions: Local reactions (erythema, irritation, pain, swelling, or tenderness) secondary to extravasation have been noted. These were generally mild and typically occurred within 24 hours of infusion. Monitor infusion site during infusion for possible infiltration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Serious hepatotoxicity, including liver failure and death, has been reported. Monitor transaminases and bilirubin at baseline and prior to each dose. Increases (transaminases or total bilirubin) may require dose reductions or discontinuation.",
"     </b>",
"     Hepatotoxicity is typically manifested by asymptomatic and transient increases in transaminases, although fatal cases of drug induced liver injury and hepatic encephalopathy have occurred; may be confounded by comorbidities or concomitant hepatotoxic medications. Use has not been studied in patients with baseline serum transaminases &gt;2.5 times ULN or bilirubin &gt;1.5 times ULN. Cases of nodular regenerative hyperplasia (NRH), a rare liver disorder characterized by widespread benign transformation of hepatic parenchyma into small regenerative nodules, have been observed (by biopsy). NRH may develop into noncirrhotic portal hypertension. Consider NRH in patients with clinical symptoms of portal hypertension without associated transaminase elevations or manifestations of cirrhosis. Permanently discontinue if histopathology confirms NRH.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity/infusion-related reactions: Infusion reactions (flushing, chills, fever, bronchospasm, dyspnea, wheezing, hypotension, and/or tachycardia) have been reported. After termination of infusion, these reactions generally resolved within several hours to a day. Medications for the treatment of reactions should be available for immediate use. Monitor closely for infusion reactions, especially during initial infusion. If reaction occurs, decrease infusion rate; for severe infusion reactions, interrupt infusion; permanently discontinue for life-threatening reactions. Serious allergic/anaphylactic reaction was observed (rare). Use is not recommended in patients who had trastuzumab permanently discontinued due to infusion reaction or hypersensitivity (has not been evaluated).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Peripheral neuropathy: Sensory peripheral neuropathy has been reported, usually grade 1. Monitor for signs and symptoms of neuropathy. May require treatment interruption and/or dose reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pulmonary toxicity: Interstitial lung disease (ILD), including pneumonitis has been reported; some cases resulted in acute respiratory distress syndrome and/or fatalities. Permanently discontinue with diagnosis of ILD or pneumonitis. Signs and symptoms of pneumonitis include dyspnea, cough, fatigue, and pulmonary infiltrates; may or may not occur in correlation with infusion reaction. Patients with dyspnea at rest (due to advance malignancy complications or comorbidity) may be at increased risk for pulmonary toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Drug-drug/drug-food interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Asian ancestry: The incidence of thrombocytopenia may be higher in patients of Asian ancestry.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Exposure to ado-trastuzumab emtansine may cause embryo-fetal death. Effective contraception must be used in women of reproductive potential.",
"     </b>",
"     Pregnancy status should be verified prior to therapy. Effective contraception is recommended during therapy and for 6 months after treatment for women of childbearing potential",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Do not interchange:",
"     <b>",
"      [U.S. Boxed Warning]: Ado-trastuzumab emtansine and conventional trastuzumab are",
"      <b>",
"       NOT",
"      </b>",
"      interchangeable.",
"     </b>",
"     Verify product label prior to reconstitution and administration to prevent medication errors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; HER2 expression: Establish HER2 overexpression or gene amplification status prior to treatment; has only been studied in patients with evidence of HER2 overexpression, either as 3+ IHC (Dako Herceptest&trade;) or FISH amplification ratio &ge;2 (Dako",
"     <i>",
"      HER2",
"     </i>",
"     FISH pharmDx&trade; test).  There is only limited data on patients with breast cancer positive by FISH and 0 or 1+ by IHC.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F16369049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F16369047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abciximab: May enhance the potential for allergic or hypersensitivity reactions to Monoclonal Antibodies. Also may cause thrombocytopenia or diminished therapeutic effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F16255121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F16255122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"     <b>",
"      [U.S. Boxed Warning]: Exposure to ado-trastuzumab emtansine may cause embryo-fetal death. Effective contraception must be used in women of reproductive potential.",
"     </b>",
"     Oligohydramnios, pulmonary hypoplasia, skeletal malformations and neonatal death were observed following trastuzumab exposure during pregnancy (trastuzumab is the antibody component of ado-trastuzumab emtansine). The DM1 component of the ado-trastuzumab emtansine formulation is toxic to rapidly dividing cells and is also expected to cause fetal harm. Pregnancy status should be verified prior to therapy. Effective contraception is recommended during therapy and for 6 months after treatment for women of childbearing potential.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     If ado-trastuzumab emtansine exposure occurs during pregnancy, healthcare providers should report the exposure to the Genentech Adverse Event Line (888-835-2555). Women exposed to ado-trastuzumab emtansine during pregnancy are encouraged to enroll in MotHER Pregnancy Registry (1-800-690-6720).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F16255123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16255124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if ado-trastuzumab emtansine is excreted into breast milk. Endogenous immunoglobulins are found in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the decision to discontinue ado-trastuzumab emtansine or discontinue breast-feeding during treatment should take in account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Kadcyla Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (1): $3328.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160 mg (1): $5325.25",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F16255365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Platelet count (at baseline and prior to each dose), transaminases and bilirubin (at baseline and prior to each dose); pregnancy status; HER2 expression status. Evaluate left ventricular function (prior to and at least every 3 months during treatment; for LVEF &lt;40% or 40% to 45% with &ge;10% absolute decrease below baseline value, reassess within 3 weeks). Monitor infusion site during infusion for possible infiltration; monitor for infusion reactions (during infusion and for 90 minutes after initial infusion and for 30 minutes after subsequent infusions); signs and symptoms of neuropathy; pulmonary toxicity",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F16255182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ado-trastuzumab emtansine is a HER2-antibody drug conjugate which incorporates the HER2 targeted actions of trastuzumab with the microtubule inhibitor DM1 (a maytansine derivative). The conjugate, which is linked via a stable thioether linker, allows for selective delivery into HER2 overexpressing cells, resulting in cell cycle arrest and apoptosis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F16255198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 3.13 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: DM1: 93%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: DM1 undergoes hepatic metabolism via CYP3A4/5",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~4 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak:  Near the end of the infusion",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Burris HA 3rd, Rugo HS, Vukelja SJ, et al, &ldquo;Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer After Prior HER2-Directed Therapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(4):398-405.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/16/11527/abstract-text/21172893/pubmed\" id=\"21172893\" target=\"_blank\">",
"        21172893",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hurvitz SA, Dirix L, Kocsis J, et al, &ldquo;Phase II Randomized Study of Trastuzumab Emtansine versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2013, 31(9):1157-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/16/11527/abstract-text/23382472/pubmed\" id=\"23382472\" target=\"_blank\">",
"        23382472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Girish S, Gupta M, Wang B, et al, &ldquo;Clinical Pharmacology of Trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate in Development for the Treatment of HER2-Positive Cancer,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2012, 69(5):1229-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/16/11527/abstract-text/22271209/pubmed\" id=\"22271209\" target=\"_blank\">",
"        22271209",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krop IE, LoRusso P, Miller KD, et al, &ldquo;A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, aTaxane, and Capecitabine,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(26):3234-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/16/11527/abstract-text/22649126/pubmed\" id=\"22649126\" target=\"_blank\">",
"        22649126",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Verma S, Miles D, Gianni L, et al, &ldquo;Trastuzumab Emtansine for HER2-positive Advanced Breast Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      ,  2012, 367(19):1783-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/16/11527/abstract-text/23020162/pubmed\" id=\"23020162\" target=\"_blank\">",
"        23020162",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 88427 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-F0C764AA00-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_16_11527=[""].join("\n");
var outline_f11_16_11527=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16248342\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16253283\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16248345\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16255288\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16255289\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16255291\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16255292\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16255290\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16253284\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16255120\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16255361\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16255181\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16248201\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16255118\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16330709\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16255125\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16255126\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16369049\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16369047\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16255121\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16255122\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16255123\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16255124\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570472\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16255365\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16255182\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16255198\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/88427\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/88427|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/41/9877?source=related_link\">",
"      Ado-trastuzumab emtansine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_16_11528="Clostridium difficile infection in children: Clinical features";
var content_f11_16_11528=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clostridium difficile infection in children: Clinical features",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/16/11528/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/16/11528/contributors\">",
"     Michael S Cooperstock, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/16/11528/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/16/11528/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/16/11528/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/16/11528/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/16/11528/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of Clostridium difficile infection in children will be discussed here. The microbiology, pathogenesis, epidemiology, diagnosis, treatment, and prevention of C. difficile infection in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16745?source=see_link\">",
"     \"Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28777?source=see_link\">",
"     \"Clostridium difficile infection in children: Approach to diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14426?source=see_link\">",
"     \"Clostridium difficile infection in children: Treatment and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clostridium difficile infection in adults also is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=see_link\">",
"     \"Clostridium difficile in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical spectrum of C. difficile infection ranges from asymptomatic carriage to fulminant life-threatening colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The severity of C. difficile infection generally increases with age. In infants and young children, the majority of cases are asymptomatic or mild. However, in all age groups, the full spectrum of disease may be possible [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In some instances, an occult, predisposing disorder may be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16745?source=see_link&amp;anchor=H17#H17\">",
"     \"Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology\", section on 'Occult underlying conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Infants and young children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants, particularly those younger than about two years of age, frequently are colonized without symptoms. Most studies have failed to demonstrate any relationship between C. difficile and common forms of diarrheal illness in this age group [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/3-11\">",
"     3-11",
"    </a>",
"    ]. The reported rates of detection of toxigenic C. difficile and C. difficile toxins have been similar in infants with and without diarrhea. The causes of this apparent resistance to illness are unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16745?source=see_link&amp;anchor=H6#H6\">",
"     \"Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among preschool-age children with diarrhea, one group found those with diarrhea had fecal C. difficile or C. difficile toxin more often than those without [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. However, most studies in this age group, both in ambulatory settings and in hospital, have found no association between diarrhea and the presence of C. difficile toxins [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/3,4,6,7\">",
"     3,4,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe illness among infants and young children with C. difficile-associated diarrhea is very uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/6,7,13,14\">",
"     6,7,13,14",
"    </a>",
"    ]. Nonetheless, several reports describe isolated cases severely ill with toxic megacolon or colitis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73501 \" href=\"UTD.htm?6/46/6888\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/4,5,15-20\">",
"     4,5,15-20",
"    </a>",
"    ]. It remains to be determined whether severe illness in children has increased with the emergence of newer hypervirulent strains.",
"   </p>",
"   <p>",
"    Furthermore, coinfection with additional intestinal pathogens is common in infants and young children (ranging from 34 to 68 percent in various studies) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/10,11,21-26\">",
"     10,11,21-26",
"    </a>",
"    ]. Many common bacterial and viral enteric agents have been identified as copathogens. The presence of C. difficile in such coinfections does not appear to be associated with increased illness severity. These observations suggest C. difficile may be an incidental finding more often than contributing to the pathogenesis of the diarrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     School-age children and adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in younger children, C. difficile infection in school-age children and adolescents without predisposing conditions usually is mild or self-limited [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. However, severe colitis and endoscopically confirmed pseudomembranous colitis have certainly been described [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Pseudomembranous colitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ASYMPTOMATIC CARRIAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic colonization with toxigenic strains of C. difficile is common among healthy infants [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Colonization rates are highest in infants younger than one year of age and gradually decrease thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/1,33\">",
"     1,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16745?source=see_link&amp;anchor=H10#H10\">",
"     \"Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology\", section on 'Prevalence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Asymptomatic carriers are an important reservoir of C. difficile, particularly in hospital nurseries, other medical facilities, and child care centers [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/1,2,12,33,34\">",
"     1,2,12,33,34",
"    </a>",
"    ]. Treatment of asymptomatic carriers with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"     metronidazole",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14426?source=see_link&amp;anchor=H3#H3\">",
"     \"Clostridium difficile infection in children: Treatment and prevention\", section on 'Asymptomatic carrier'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of C. difficile infection in antibiotic-associated cases typically begin either during or shortly after antibiotic therapy, but occasionally the onset is delayed for as long as 6 to 10 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multicenter Canadian survey identified 97 pediatric hospitalizations for C. difficile disease in a six-month period during 2004-2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/35\">",
"     35",
"    </a>",
"    ]. The median age was five years. Fewer than 10 percent were hypervirulent strains",
"    <span class=\"nowrap\">",
"     (BI/NAP1/027)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/35\">",
"     35",
"    </a>",
"    ]. More than one-third of the cases were community acquired. Most had a benign course. However, poor outcomes occurred in 5 percent: two children died, one survived after colectomy, and two had relapses [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild to moderate diarrhea is the most common presentation of symptomatic C. difficile [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/2,27,30\">",
"     2,27,30",
"    </a>",
"    ]. The diarrhea may be accompanied by lower abdominal cramping. The physical examination typically is normal or may demonstrate lower abdominal tenderness [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A report on 200 children with C. difficile-associated diarrhea from Montreal during 2000-2003, median age 2.6 years, found 79 percent had frequent watery stools, and 13 percent had bloody stools [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/27\">",
"     27",
"    </a>",
"    ]. Laboratory findings, strain typing, and radiographic findings were not reported.",
"   </p>",
"   <p>",
"    In a case-control study of antibiotic-associated diarrhea in hospitalized children (age 5 to 12 years), the clinical features of C. difficile infection in 45 children included fever (84 percent), fecal leukocytes (42 percent), abdominal pain (40 percent), &gt;10 stools per day (27 percent), and fecal mucus or blood (24 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/30\">",
"     30",
"    </a>",
"    ]. Endoscopies were not reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pseudomembranous colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudomembranous colitis is an endoscopic or histologic diagnosis. In adults, clinical findings associated with pseudomembranous colitis include severe diarrhea, abdominal pain, abdominal distention, and systemic symptoms (eg, fever, anorexia, malaise) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/2\">",
"     2",
"    </a>",
"    ]. Although not usually performed in children, sigmoidoscopy or colonoscopy demonstrates characteristic adherent yellow plaques (",
"    <a class=\"graphic graphic_picture graphicRef53774 \" href=\"UTD.htm?38/28/39363\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef62422 \" href=\"UTD.htm?4/15/4337\">",
"     picture 2",
"    </a>",
"    ). Immediate treatment is crucial to prevent progression to more severe disease (eg, toxic megacolon). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14426?source=see_link&amp;anchor=H4#H4\">",
"     \"Clostridium difficile infection in children: Treatment and prevention\", section on 'Symptomatic patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fully expressed C. difficile pseudomembranous colitis is relatively uncommon during childhood. There are a few isolated case reports of severe or fatal pseudomembranous colitis in neonates and infants younger than two years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/4,15-20\">",
"     4,15-20",
"    </a>",
"    ]. In some, but not all, cases the infant (or a breast-feeding mother) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/19\">",
"     19",
"    </a>",
"    ] had received prior antibiotics. Some of the infants were previously healthy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/16\">",
"     16",
"    </a>",
"    ]; others had potentially predisposing conditions, such as gastrointestinal obstruction or prematurity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. No other explanation for pseudomembranous colitis was found in these cases. However, given the high frequency of toxigenic C. difficile carriage in this age group, it is impossible to know definitively whether C. difficile was a causal or incidental finding.",
"   </p>",
"   <p>",
"    Similarly, there are only a few published reports of endoscopically documented pseudomembranous C. difficile colitis in children older than two years without predisposing conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/29,36-39\">",
"     29,36-39",
"    </a>",
"    ], perhaps in part because children with C. difficile infection are often diagnosed and treated without endoscopy. The cases that have been described appear to be similar to those in adults. Although case descriptions were often incomplete, the clinical findings included [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/29,36-41\">",
"     29,36-41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Onset during or within 21 days after administration of &ge;1 antibiotic",
"     </li>",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Prolonged watery diarrhea",
"     </li>",
"     <li>",
"      Abdominal pain and distention",
"     </li>",
"     <li>",
"      Blood or mucus in the stool",
"     </li>",
"     <li>",
"      Neutrophilia and increased band counts",
"     </li>",
"     <li>",
"      Fecal leukocytes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most severe cases often had dehydration and hypoproteinemia; several had sepsis, ascites, or pleural effusion. Intestinal perforation, ileocolic intussusception, pneumatosis intestinalis, and rectal prolapse (with pseudomembranes visible on the extruded segment) were rare manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/36-41\">",
"     36-41",
"    </a>",
"    ]. Paralytic ileus may lead to a paradoxical absence of stool, which may delay diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/2\">",
"     2",
"    </a>",
"    ]. In severe cases, characteristic radiologic changes are often present. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Radiographic features'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A study of pathologic findings in seven fatal cases of pseudomembranous colitis in children with predisposing conditions reported diffuse colonic involvement, often extending into the distal ileum (in four children with Hirschsprung disease), and focal colonic disease (in three children with neutropenia and hematologic malignancy) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/42\">",
"     42",
"    </a>",
"    ]. C. difficile was seen only in diseased colon tissue, where it had invaded to the base of colon crypts or to the submucosa, strongly supporting a causal relationship. Two cases had detectable C. difficile cytotoxin in ascitic fluid or serum.",
"   </p>",
"   <p>",
"    Other microbial causes for pseudomembranous colitis have been described. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28777?source=see_link&amp;anchor=H25#H25\">",
"     \"Clostridium difficile infection in children: Approach to diagnosis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Recurrent infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent C. difficile infection is defined by a return of the infection after a period of symptom resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/43\">",
"     43",
"    </a>",
"    ]. It generally occurs one to three weeks after the initial episode but has been described up to two months later [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrent C. difficile diarrhea in children, whether relapse with the original organism or reinfection with a new strain, has been rare. Recurrence has been reported in individual cases and case series [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/24,27,45,46\">",
"     24,27,45,46",
"    </a>",
"    ]. Studies describing C. difficile infection in children published before 2000 rarely mention recurrences. However, as in adults, relapses of C. difficile infection in children may be increasing in frequency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link&amp;anchor=H9#H9\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\", section on 'Recurrent disease: relapse vs reinfection'",
"    </a>",
"    .) In a multicenter Canadian study in which &lt;10 percent of children with C. difficile infection had hypervirulent strains",
"    <span class=\"nowrap\">",
"     (BI/NAP1/027),",
"    </span>",
"    relapses occurred in only 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/35\">",
"     35",
"    </a>",
"    ]. However, in a 2005 review of 200 children with C. difficile-associated diarrhea in Montreal during a period of",
"    <span class=\"nowrap\">",
"     BI/NAP1/027",
"    </span>",
"    ascendancy, 31 percent of 110 children had recurrences after successful treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"     metronidazole",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrence in adults may be due to reinfection with a new strain about as often as it is due to relapse with the original organism, and this may be true in children, as well [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link&amp;anchor=H9#H9\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\", section on 'Recurrent disease: relapse vs reinfection'",
"    </a>",
"    .) This suggests that the host may remain susceptible after successful treatment and that many recurrences may be prevented through adherence to good infection control practice and avoidance of further antimicrobial treatment or hospitalization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14426?source=see_link&amp;anchor=H80878967#H80878967\">",
"     \"Clostridium difficile infection in children: Treatment and prevention\", section on 'Prevention of recurrence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recurrence of C. difficile infection in children may be an indication of immunodeficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16745?source=see_link&amp;anchor=H19#H19\">",
"     \"Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology\", section on 'Other conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chronic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In small pediatric case series, C. difficile has been associated with chronic persistent diarrhea and other gastrointestinal symptoms, such as malnutrition, anorexia, poor growth, abdominal distension, or emesis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/24,49-52\">",
"     24,49-52",
"    </a>",
"    ]. In some cases, the symptoms resolved after",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/49-51\">",
"     49-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These studies suggest that C. difficile may contribute to a variety of chronic (and clinically difficult) gastrointestinal disorders in young children, although this hypothesis remains to be established. Most of the children included in the studies were in an age group in which colonization with toxigenic C. difficile would be expected as a common incidental finding. Larger, prospective studies have failed to confirm an association between fecal C. difficile toxin and chronic diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Reactive arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of cases of sterile mono- or polyarticular reactive arthritis after C. difficile infection have been described in adults and children [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/55-58\">",
"     55-58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link&amp;anchor=H5#H5\">",
"     \"Reactive arthritis (formerly Reiter syndrome)\", section on 'Preceding infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hypervirulent strain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spectrum of illness due to hypervirulent",
"    <span class=\"nowrap\">",
"     (BI/NAP1/027)",
"    </span>",
"    C. difficile has not yet been well described in children. In the Canadian Nosocomial Infection Surveillance Program (2004-2005), children with hypervirulent C. difficile infection were more likely to have complications than children who had other strains (29 versus 6 percent, relative risk 4.6, 95% CI 1.1-17.2) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/35\">",
"     35",
"    </a>",
"    ]. However, asymptomatic fecal carriage of",
"    <span class=\"nowrap\">",
"     BI/NAP1/027",
"    </span>",
"    has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     LABORATORY FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory features of C. difficile infection may include [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/29,36-41\">",
"     29,36-41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevation of inflammatory markers, including leukocytosis, neutrophilia, immature neutrophils, erythrocyte sedimentation rate, or C-reactive protein. Peripheral white blood cell counts &gt;15,000",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      have been reported to be an early marker of C. difficile infection in adult patients evaluated before the onset of diarrhea [",
"      <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/59,60\">",
"       59,60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Blood in the stool",
"     </li>",
"     <li>",
"      Fecal leukocytes may present in up to 50 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/61,62\">",
"       61,62",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the presence of symptoms of C. difficile infection, stool tests positive for C. difficile toxin(s)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    toxigenic C. difficile are required for diagnosis. Endoscopic visualization of pseudomembranes is also highly suggestive, even with negative toxin assays. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28777?source=see_link&amp;anchor=H17#H17\">",
"     \"Clostridium difficile infection in children: Approach to diagnosis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28777?source=see_link&amp;anchor=H21#H21\">",
"     \"Clostridium difficile infection in children: Approach to diagnosis\", section on 'Endoscopy'",
"    </a>",
"    .) Luminal specimens obtained endoscopically may also be tested for toxin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic features of severe C. difficile infection may include thickened bowel wall evident on plain film or ultrasonography (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52929 \" href=\"UTD.htm?32/51/33598\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52523 \" href=\"UTD.htm?25/62/26593\">",
"     image 3",
"    </a>",
"    ). However, radiographic changes of C. difficile are best demonstrated by computed tomography (CT) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73501 \" href=\"UTD.htm?6/46/6888\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11528/abstract/2,61-63\">",
"     2,61-63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thickened colon wall",
"     </li>",
"     <li>",
"      \"Accordion sign\" created by contrast or gas trapped between swollen haustra (on ultrasonography or CT)",
"     </li>",
"     <li>",
"      Wall nodularity",
"     </li>",
"     <li>",
"      Pericolonic stranding",
"     </li>",
"     <li>",
"      Ascites",
"     </li>",
"     <li>",
"      Dilated colon in patients with paralytic ileus or toxic megacolon (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef59217 \" href=\"UTD.htm?10/11/10416\">",
"       image 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Free air (in patients with colonic perforation)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical spectrum of Clostridium difficile infection ranges from asymptomatic carriage to fulminant colitis. The severity of C. difficile infection increases with age. In infants and young children, the majority of cases are relatively mild, and in most young children, the detection of C. difficile or its toxin is probably incidental. However, in all age groups, the full spectrum of disease is possible. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms of C. difficile infection in antibiotic-associated cases typically begin either during or within a few weeks after antibiotic therapy. Mild to moderate diarrhea is the most common presentation of symptomatic C. difficile infection. The diarrhea is usually watery and may be accompanied by abdominal pain, fever, and other systemic signs. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diarrhea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fully expressed pseudomembranous colitis is uncommon during childhood. Clinical findings may include fever, prolonged watery diarrhea, abdominal pain and distension, blood or mucus in the stool, neutrophilia, increased band counts, and fecal leukocytes. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pseudomembranous colitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The spectrum of illness due to hypervirulent",
"      <span class=\"nowrap\">",
"       (BI/NAP1/027)",
"      </span>",
"      C. difficile in children has not yet been fully described. A range from asymptomatic carriage to severe illness with complications has been reported. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Hypervirulent strain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory features of C. difficile infection may include elevation of inflammatory markers, blood in the stool, and fecal leukocytes. Peripheral white blood cell counts &gt;15,000",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      may be an early marker of C. difficile infection in the appropriate clinical setting. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Laboratory features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If endoscopy is not performed, radiologic changes may indicate disease severity. Radiographic features of severe C. difficile infection may include thickening or nodularity of the colon wall (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef73501 \" href=\"UTD.htm?6/46/6888\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52929 \" href=\"UTD.htm?32/51/33598\">",
"       image 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52523 \" href=\"UTD.htm?25/62/26593\">",
"       image 3",
"      </a>",
"      ), contrast or gas trapped between swollen haustra (accordion sign), pericolonic stranding, ascites, colonic dilation (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef59217 \" href=\"UTD.htm?10/11/10416\">",
"       image 4",
"      </a>",
"      ), or free air. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Radiographic features'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author gratefully acknowledges the assistance of Caryn Scoville, librarian III and Information Services librarian, University of Missouri Libraries, and Brian Green, MD, Department of Radiology, University of Missouri Health Care.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/1\">",
"      Bryant K, McDonald LC. Clostridium difficile infections in children. Pediatr Infect Dis J 2009; 28:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/2\">",
"      Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/3\">",
"      Karsch W, Strelau E, Grahlow WD, et al. Occurrence and significance of Clostridium difficile in faecal specimens of hospitalized children. Zentralbl Bakteriol Mikrobiol Hyg A 1989; 270:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/4\">",
"      Ellis ME, Mandal BK, Dunbar EM, Bundell KR. Clostridium difficile and its cytotoxin in infants admitted to hospital with infectious gastroenteritis. Br Med J (Clin Res Ed) 1984; 288:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/5\">",
"      Libby JM, Donta ST, Wilkins TD. Clostridium difficile toxin A in infants. J Infect Dis 1983; 148:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/6\">",
"      Cerquetti M, Luzzi I, Caprioli A, et al. Role of Clostridium difficile in childhood diarrhea. Pediatr Infect Dis J 1995; 14:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/7\">",
"      Vernacchio L, Vezina RM, Mitchell AA, et al. Diarrhea in American infants and young children in the community setting: incidence, clinical presentation and microbiology. Pediatr Infect Dis J 2006; 25:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/8\">",
"      M&aring;rdh PA, Helin I, Colleen I, et al. Clostridium difficile toxin in faecal specimens of healthy children and children with diarrhoea. Acta Paediatr Scand 1982; 71:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/9\">",
"      Svedhem A, Kaijser B, MacDowall I. Intestinal occurrence of Campylobacter fetus subspecies jejuni and Clostridium difficile in children in Sweden. Eur J Clin Microbiol 1982; 1:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/10\">",
"      Kotloff KL, Wade JC, Morris JG Jr. Lack of association between Clostridium difficile toxin and diarrhea in infants. Pediatr Infect Dis J 1988; 7:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/11\">",
"      Tang P, Roscoe M, Richardson SE. Limited clinical utility of Clostridium difficile toxin testing in infants in a pediatric hospital. Diagn Microbiol Infect Dis 2005; 52:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/12\">",
"      Kim K, DuPont HL, Pickering LK. Outbreaks of diarrhea associated with Clostridium difficile and its toxin in day-care centers: evidence of person-to-person spread. J Pediatr 1983; 102:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/13\">",
"      Mitchell DK, Van R, Mason EH, et al. Prospective study of toxigenic Clostridium difficile in children given amoxicillin/clavulanate for otitis media. Pediatr Infect Dis J 1996; 15:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/14\">",
"      Denno DM, Stapp JR, Boster DR, et al. Etiology of diarrhea in pediatric outpatient settings. Pediatr Infect Dis J 2005; 24:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/15\">",
"      Adler SP, Chandrika T, Berman WF. Clostridium difficile associated with pseudomembranous colitis. Occurrence in a 12-week-old infant without prior antibiotic therapy. Am J Dis Child 1981; 135:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/16\">",
"      Richardson SA, Brookfield DS, French TA, Gray J. Pseudomembranous colitis in a 5-week-old infant. Br Med J (Clin Res Ed) 1981; 283:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/17\">",
"      Perelman R, Rowe JC, Christie DL, Hodson WA. Pseudomembranous colitis following obstruction in a neonate. Clin Pediatr (Phila) 1981; 20:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/18\">",
"      Singer DB, Cashore WJ, Widness JA, et al. Pseudomembranous colitis in a preterm neonate. J Pediatr Gastroenterol Nutr 1986; 5:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/19\">",
"      Harmon T, Burkhart G, Applebaum H. Perforated pseudomembranous colitis in the breast-fed infant. J Pediatr Surg 1992; 27:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/20\">",
"      Mandal BK, Watson B, Ellis M. Pseudomembranous colitis in a 5-week-old infant. Br Med J (Clin Res Ed) 1982; 284:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/21\">",
"      Klein EJ, Boster DR, Stapp JR, et al. Diarrhea etiology in a Children's Hospital Emergency Department: a prospective cohort study. Clin Infect Dis 2006; 43:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/22\">",
"      Rexach CE, Tang-Feldman YJ, Cantrell MC, Cohen SH. Epidemiologic surveillance of Clostridium difficile diarrhea in a freestanding pediatric hospital and a pediatric hospital at a university medical center. Diagn Microbiol Infect Dis 2006; 56:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/23\">",
"      O��uz F, Uysal G, Da��demir S, et al. The role of Clostridium difficile in childhood nosocomial diarrhea. Scand J Infect Dis 2001; 33:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/24\">",
"      Tvede M, Schi&oslash;tz PO, Krasilnikoff PA. Incidence of Clostridium difficile in hospitalized children. A prospective study. Acta Paediatr Scand 1990; 79:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/25\">",
"      Rosenfeldt V, Vesikari T, Pang XL, et al. Viral etiology and incidence of acute gastroenteritis in young children attending day-care centers. Pediatr Infect Dis J 2005; 24:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/26\">",
"      Lukkarinen H, Eerola E, Ruohola A, et al. Clostridium difficile ribotype 027-associated disease in children with norovirus infection. Pediatr Infect Dis J 2009; 28:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/27\">",
"      Morinville V, McDonald J. Clostridium difficile-associated diarrhea in 200 Canadian children. Can J Gastroenterol 2005; 19:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/28\">",
"      Kim J, Smathers SA, Prasad P, et al. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics 2008; 122:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/29\">",
"      Viscidi RP, Bartlett JG. Antibiotic-associated pseudomembranous colitis in children. Pediatrics 1981; 67:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/30\">",
"      Gogate A, De A, Nanivadekar R, et al. Diagnostic role of stool culture &amp; toxin detection in antibiotic associated diarrhoea due to Clostridium difficile in children. Indian J Med Res 2005; 122:518.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Clostridium difficile. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LJ.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.285.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/32\">",
"      Schutze GE, Willoughby RE, Committee on Infectious Diseases, American Academy of Pediatrics. Clostridium difficile infection in infants and children. Pediatrics 2013; 131:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/33\">",
"      Holst E, Helin I, M&aring;rdh PA. Recovery of Clostridium difficile from children. Scand J Infect Dis 1981; 13:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/34\">",
"      Hecker MT, Riggs MM, Hoyen CK, et al. Recurrent infection with epidemic Clostridium difficile in a peripartum woman whose infant was asymptomatically colonized with the same strain. Clin Infect Dis 2008; 46:956.",
"     </a>",
"    </li>",
"    <li>",
"     Suh, KN, Gravel, D, Mulvey, MR, et al. Clostridium difficile-associated infections in children admitted to acute care hospitals participating in the Canadian Nosocomial Infections Surveillance Program (CNISP), 2004-2005 [abstract 306]. In: Program of the 18th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America (April 2008). The Society for Healthcare Epidemiology of America, Orlando, FL 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/36\">",
"      Zwiener RJ, Belknap WM, Quan R. Severe pseudomembranous enterocolitis in a child: case report and literature review. Pediatr Infect Dis J 1989; 8:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/37\">",
"      Harris PR, Figueroa-Colon R. Rectal prolapse in children associated with Clostridium difficile infection. Pediatr Infect Dis J 1995; 14:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/38\">",
"      Park JH, Chung MH, Kim JY, et al. Intussusception associated with pseudomembranous colitis. J Pediatr Gastroenterol Nutr 2008; 46:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/39\">",
"      Fitzgerald J, Troncone R, Cole CR, Kaul A. Clinical quiz. An ileocolonic intussusception associated with C. difficile infection. J Pediatr Gastroenterol Nutr 2001; 33:289, 300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/40\">",
"      Gillett PM, Russell RK, Wilson DC, Thomas AE. C difficile induced pneumatosis intestinalis in a neutropenic child. Arch Dis Child 2002; 87:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/41\">",
"      Burton EM, Mercado-Deane MG, Patel K. Pneumatosis intestinalis in a child with AIDS and pseudomembranous colitis. Pediatr Radiol 1994; 24:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/42\">",
"      Qualman SJ, Petric M, Karmali MA, et al. Clostridium difficile invasion and toxin circulation in fatal pediatric pseudomembranous colitis. Am J Clin Pathol 1990; 94:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/43\">",
"      Shannon-Lowe J, Matheson NJ, Cooke FJ, Aliyu SH. Prevention and medical management of Clostridium difficile infection. BMJ 2010; 340:c1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/44\">",
"      P&eacute;pin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006; 42:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/45\">",
"      Holmes R, Byrne WJ. Relapsing pseudomembranous colitis. J Pediatr Gastroenterol Nutr 1986; 5:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/46\">",
"      Leung DY, Kelly CP, Boguniewicz M, et al. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991; 118:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/47\">",
"      Kato H, Kato N, Watanabe K, et al. Relapses or reinfections: analysis of a case of Clostridium difficile-associated colitis by two typing systems. Curr Microbiol 1996; 33:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/48\">",
"      Gryboski JD, Pellerano R, Young N, Edberg S. Positive role of Clostridium difficile infection in diarrhea in infants and children. Am J Gastroenterol 1991; 86:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/49\">",
"      Sutphen JL, Grand RJ, Flores A, et al. Chronic diarrhea associated with Clostridium difficile in children. Am J Dis Child 1983; 137:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/50\">",
"      Liston TE. Clostridium difficile toxin associated with chronic diarrhea and failure to gain weight. Clin Pediatr (Phila) 1983; 22:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/51\">",
"      Buts JP, Corthier G, Delmee M. Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants. J Pediatr Gastroenterol Nutr 1993; 16:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/52\">",
"      Gianerilli P, Luzzi I, Occhionero M, et al. Clostridium difficile and Clostridium perfringens in upper gut of infants with protracted diarrhoea. J Clin Pathol 1985; 38:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/53\">",
"      de Boissieu D, Chaussain M, Badoual J, et al. Small-bowel bacterial overgrowth in children with chronic diarrhea, abdominal pain, or both. J Pediatr 1996; 128:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/54\">",
"      Vernacchio L, Vezina RM, Mitchell AA, et al. Characteristics of persistent diarrhea in a community-based cohort of young US children. J Pediatr Gastroenterol Nutr 2006; 43:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/55\">",
"      Jacobs A, Barnard K, Fishel R, Gradon JD. Extracolonic manifestations of Clostridium difficile infections. Presentation of 2 cases and review of the literature. Medicine (Baltimore) 2001; 80:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/56\">",
"      Cron RQ, Gordon PV. Reactive arthritis to Clostridium difficile in a child. West J Med 1997; 166:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/57\">",
"      Durand CL, Miller PF. Severe Clostridium difficile colitis and reactive arthritis in a ten-year-old child. Pediatr Infect Dis J 2009; 28:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/58\">",
"      L&ouml;ffler HA, Pron B, Mouy R, et al. Clostridium difficile-associated reactive arthritis in two children. Joint Bone Spine 2004; 71:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/59\">",
"      Bulusu M, Narayan S, Shetler K, Triadafilopoulos G. Leukocytosis as a harbinger and surrogate marker of Clostridium difficile infection in hospitalized patients with diarrhea. Am J Gastroenterol 2000; 95:3137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/60\">",
"      Wanahita A, Goldsmith EA, Marino BJ, Musher DM. Clostridium difficile infection in patients with unexplained leukocytosis. Am J Med 2003; 115:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/61\">",
"      Fekety R, Shah AB. Diagnosis and treatment of Clostridium difficile colitis. JAMA 1993; 269:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/62\">",
"      Reddymasu S, Sheth A, Banks DE. Is Fecal Leukocyte Test a good predictor of Clostridium difficile associated diarrhea? Ann Clin Microbiol Antimicrob 2006; 5:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11528/abstract/63\">",
"      Blickman JG, Boland GW, Cleveland RH, et al. Pseudomembranous colitis: CT findings in children. Pediatr Radiol 1995; 25 Suppl 1:S157.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6048 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-2AD339225F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_16_11528=[""].join("\n");
var outline_f11_16_11528=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Infants and young children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      School-age children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ASYMPTOMATIC CARRIAGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pseudomembranous colitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Recurrent infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chronic symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Reactive arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hypervirulent strain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      LABORATORY FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RADIOGRAPHIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6048\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6048|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/46/6888\" title=\"diagnostic image 1\">",
"      C difficile colitis child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/51/33598\" title=\"diagnostic image 2\">",
"      Thumbprinting C difficile",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/62/26593\" title=\"diagnostic image 3\">",
"      C difficile sonogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/11/10416\" title=\"diagnostic image 4\">",
"      Toxic megacolon in C diff",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6048|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/28/39363\" title=\"picture 1\">",
"      Pseudomembranous colitis scope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/15/4337\" title=\"picture 2\">",
"      Pseudomembranous colitis Gross",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=related_link\">",
"      Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=related_link\">",
"      Clostridium difficile in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28777?source=related_link\">",
"      Clostridium difficile infection in children: Approach to diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16745?source=related_link\">",
"      Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14426?source=related_link\">",
"      Clostridium difficile infection in children: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=related_link\">",
"      Reactive arthritis (formerly Reiter syndrome)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_16_11529="Enteral nutrition in infants and children";
var content_f11_16_11529=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Enteral nutrition in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/16/11529/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/16/11529/contributors\">",
"     Sharon Collier, RD, MEd",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/16/11529/contributors\">",
"     Christopher Duggan, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/16/11529/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/16/11529/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/16/11529/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/16/11529/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/16/11529/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H4320415\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteral nutrition consists of providing nutrients via the gastrointestinal tract. Although the term technically refers to nutrition given either by mouth or through a feeding tube, in common usage the term usually refers to tube feeding. In comparison to parenteral nutrition (the provision of nutrients via a venous catheter directly into the bloodstream), enteral nutrition offers several advantages, including lower costs, beneficial effects from utilization of the gastrointestinal tract, and avoidance of the many potential complications of parenteral nutrition.",
"   </p>",
"   <p>",
"    For many pediatric patients with suboptimal nutrition, intake by mouth can be improved by offering high-calorie foods, oral supplements, or boosting the nutrient density of foods by adding high-energy supplements such as fats (oils, cream, or butter), carbohydrates (sugars and powdered supplements), and proteins (milk or other protein powders). Children who are still unable to take in sufficient energy through these approaches, or those who are unable to tolerate oral feedings because of the underlying disease, are candidates for enteral nutrition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4320422\">",
"    <span class=\"h1\">",
"     NUTRITIONAL ASSESSMENT IN CHILDREN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision about whether to initiate enteral nutrition in children should begin with a thorough and valid measure of nutritional status.",
"   </p>",
"   <p>",
"    For premature infants, evaluation of the degree of prematurity is critical and often leads to a decision to initiate tube feedings until oral feeds are possible. Enteral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    parenteral nutrition usually is required until a premature infant reaches approximately 34 weeks gestational age. Appropriate growth curves or correction for gestational age should be employed when judging the nutritional status of premature infants. The evaluation for and management of enteral feeds in premature infants are discussed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/8/19593?source=see_link\">",
"     \"Approach to enteral nutrition in the premature infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23912?source=see_link&amp;anchor=H3#H3\">",
"     \"Growth management in preterm infants\", section on 'Normative growth data'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    In full-term infants and children, plotting and interpreting weight, length, and head circumference on sex- and age-specific growth curves is the hallmark of nutrition assessment. Although data from national surveys from the US government have been the commonly used standards for decades, the Centers for Disease Control and Prevention (CDC) now endorses the use of World Health Organization (WHO) growth standards for infants and children younger than two years of age; these standards were derived from healthy infants who were exclusively breastfed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11529/abstract/1\">",
"     1",
"    </a>",
"    ]. For children 2 to 20 years old in the United States, the CDC recommends use of the growth references developed in 2000. These growth charts include curves for weight for age, length (height) for age, as well as body mass index (BMI) on which individual points can be plotted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31976?source=see_link&amp;anchor=H31542395#H31542395\">",
"     \"Measurement of growth in children\", section on 'Recommended growth charts'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Several different schemes have been proposed for interpretation of anthropometric data to classify degrees of malnutrition, including the methods of Gomez, Waterlow, and others. In general, deficits in weight for age are classified as \"underweight\", deficits in length for age are classified as \"stunting\", and deficits of weight for length are classified as \"wasting\". Details and comparison of techniques for assessing malnutrition in children are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32248?source=see_link&amp;anchor=H6#H6\">",
"     \"Malnutrition in developing countries: Clinical assessment\", section on 'Assessment of severity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anthropometric measures of the arm provide helpful and supplementary data, especially in clinical scenarios when measurement of body weight is not possible or is altered by severe edema, or when height cannot be accurately measured (eg, cerebral palsy, critical illness). These include measures of triceps",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biceps skin fold thickness (TSF and BSF, respectively), and mid-upper arm circumference (MUAC). TSF and BSF are measured with a skin fold caliper, and MUAC with a non-stretchable tape measure, both measured by trained personnel. Standard equations can calculate mid-arm muscle area (MAMA) from TSF and MUAC. MAMA is an estimate of peripheral lean body mass, and TSF and BSF are reasonable estimates of peripheral body fat composition (though not central adiposity). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/38/6760?source=see_link\">",
"     \"Measurement of body composition in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/38/6760?source=see_link&amp;anchor=H11#H11\">",
"     \"Measurement of body composition in children\", section on 'Anthropometrics'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Subjective global assessment of nutritional status by the clinician includes historical information about weight loss, edema, anorexia, vomiting, diarrhea, appetite, and underlying chronic illness. This subjective assessment is correlated with objective measures of nutritional status in adults and children, and is a valuable component of assessing the patient&rsquo;s nutritional status and potential need for supplemental nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11529/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4320429\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ENTERAL NUTRITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteral nutrition should be considered when a child is unable to meet nutritional requirements by mouth. The decision to treat and the route of supplementation depends on the severity of the condition, the anticipated course of any underlying disease, and several other patient-specific considerations.",
"   </p>",
"   <p>",
"    Regardless of the technique used for nutritional assessment, pre-existing undernutrition (as defined by low birthweight, underweight, or wasting) is an indication to begin enteral nutrition sooner than among well-nourished subjects. In under-nourished infants and children, repletion of body weight is a primary goal for enteral nutrition and measure of its efficacy.",
"   </p>",
"   <p>",
"    The following general categories are common indications for enteral nutrition:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8040962\">",
"    <span class=\"h2\">",
"     Decreased ability to ingest nutrients by mouth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Underlying conditions include cerebral palsy or other neurologic problems (resulting in spasticity or poor coordination of skeletal muscles involved in eating), congenital anomalies of the gastrointestinal tract, and prematurity (in which developmental skills in oral intake are incomplete).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8040969\">",
"    <span class=\"h2\">",
"     Inability to meet increased metabolic demands through oral nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with sepsis, congenital heart disease, or bronchopulmonary dysplasia or children with critical illness commonly require enteral feeding to meet their nutrient needs, which are increased by the illness. As compared with adults, infants and children have proportionately lower reserves of body protein, carbohydrate, and fat, and also have increased metabolic needs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11529/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. As a result, the threshold for beginning supplemental enteral nutrition is also lower than in adults: In infants and children with these diseases, insufficient oral intake for three to five days is a suitable threshold for intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8040976\">",
"    <span class=\"h2\">",
"     Altered absorption or digestion requiring modification of dietary intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;This broad category includes children with short bowel syndrome, cystic fibrosis, Crohn&rsquo;s disease, some inborn errors of metabolism, chronic renal insufficiency, and others. The indications and type of enteral nutrition varies depending on the underlying condition, as discussed in the following section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4320436\">",
"    <span class=\"h1\">",
"     DISEASE-SPECIFIC CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4320443\">",
"    <span class=\"h2\">",
"     Cardiorespiratory diseases",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Congenital heart disease",
"      </strong>",
"      &ndash; Growth failure is a common complication of congenital heart disease. Malnutrition is probably caused by several mechanisms: These patients often have increased energy requirements due to increased work of breathing and cardiac effort, and may have malabsorption from poor oxygen delivery to the intestine. In addition, they often have inadequate energy intake because of anorexia, early satiety, and general feeding intolerance, caused by congestive heart failure which leads to dyspnea, tachycardia, and fatigue [",
"      <a class=\"abstract\" href=\"UTD.htm?11/16/11529/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. The severity and type of growth failure depends in part on the type of cardiac defect: cyanotic defects are typically associated with poor gains in both weight and length, while infants with acyanotic defects have poor weight gain but relatively preserved linear growth. Chronic hypoxia can be another factor resulting in poor growth.",
"      <br/>",
"      <br/>",
"      Children with growth failure due to congenital heart disease usually are not able to meet their energy needs with oral feeds alone, and often require enteral feeding support. In some cases, infants and young children with congenital heart disease also have ischemic bowel disease, with mucosal damage and sometimes requiring surgical resection, so specialized formulas may be indicated. However, the majority of children with CHD can tolerate enteral feeding with intact protein formulas. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/55/34680?source=see_link&amp;anchor=H6#H6\">",
"       \"Management of isolated ventricular septal defects in infants and children\", section on 'Dietary interventions'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43048?source=see_link\">",
"       \"Diagnosis and initial management of cyanotic heart disease in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Cystic fibrosis",
"      </strong>",
"      &ndash; Children with cystic fibrosis frequently have growth failure, caused by the combination of malabsorption, increased energy needs, and reduced appetite. Initiation of enteral feedings is appropriate if the child&rsquo;s body mass index cannot be kept in the target range (BMI at or above the 50",
"      <sup>",
"       th",
"      </sup>",
"      percentile for age) despite optimization of pancreatic enzyme therapy and oral nutrition support. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/24/15754?source=see_link&amp;anchor=H23#H23\">",
"       \"Cystic fibrosis: Nutritional issues\", section on 'Nutrition support'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4320450\">",
"    <span class=\"h2\">",
"     Gastrointestinal disease and dysfunction",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Short bowel syndrome",
"      </strong>",
"      &ndash; Both enteral and parenteral feeding are required for many infants and children with short bowel syndrome. Even small quantities of enteral feeding promote intestinal adaptation and enhance feeding tolerance; continuous feeding is usually better tolerated than bolus feeding. Over time, enteral feeds can and should be gradually increased to supply an increasing proportion of the patient&rsquo;s nutritional needs. Reducing dependence of parenteral nutrition is particularly important in infants with short bowel syndrome, who are at high risk for developing parenteral nutrition-associated liver disease (PNALD) and recurrent central venous line infections. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26778?source=see_link&amp;anchor=H9#H9\">",
"       \"Management of the short bowel syndrome in children\", section on 'Enteral feeding'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18730?source=see_link\">",
"       \"Parenteral nutrition-associated liver disease in infants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Crohn&rsquo;s disease",
"      </strong>",
"      &ndash; Children with inflammatory bowel disease (IBD), and particularly those with Crohn&rsquo;s disease, frequently have nutritionally-mediated deficits in growth which often precede the diagnosis of the IBD. At the time of diagnosis of Crohn&rsquo;s disease, approximately 25 percent of children have low body weight, 80 percent have reduced height velocity, and most have delayed pubertal development. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2794?source=see_link&amp;anchor=H12#H12\">",
"       \"Growth failure and poor weight gain in children with inflammatory bowel disease\", section on 'Clinical consequences'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Nutritional support for children and adolescents with inflammatory bowel disease depends on the degree of nutritional deficits and response to medical treatment of the IBD, ranging from dietary counseling, to liquid supplements taken by mouth, to supplemental enteral nutrition. Close monitoring of nutritional status and growth and a proactive approach to supplemental nutrition is important to optimize growth and minimize consequences of malnutrition, including bone disease. In some cases, exclusive enteral nutrition (in which all nutritional needs are supplied as a liquid formula, taken by mouth or through enteral feeds), is used as primary therapy for the IBD itself. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2794?source=see_link&amp;anchor=H26#H26\">",
"       \"Growth failure and poor weight gain in children with inflammatory bowel disease\", section on 'Intervention'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41722?source=see_link&amp;anchor=H26#H26\">",
"       \"Overview of the management of Crohn's disease in children and adolescents\", section on 'Exclusive enteral nutrition'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Biliary atresia",
"      </strong>",
"      &ndash; Nutritional problems in infants and children with biliary atresia and other cases of chronic cholestatic liver disease are common and difficult to overcome. They are caused by a combination of malabsorption due to cholestasis and chronic liver inflammation. Depending on the severity of the nutritional deficit, this is managed by increasing the energy content of oral feeds or by enteral nutrition, given by nasogastric tube",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      changing to a formula with higher MCT oil content. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39929?source=see_link&amp;anchor=H19844523#H19844523\">",
"       \"Biliary atresia\", section on 'Nutrition'",
"      </a>",
"      .)",
"      <strong>",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4422335\">",
"    <span class=\"h2\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with chronic kidney disease (CKD) frequently have nutritional problems due to poor appetite, decreased intestinal absorption of nutrients, and metabolic acidosis, which can impair growth and cognitive development. Nutritional management of children with CKD focuses on their unique energy, protein, vitamin, mineral, and electrolyte needs, and is discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of the management of chronic kidney disease in children\", section on 'Nutrition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9242?source=see_link&amp;anchor=H6760122#H6760122\">",
"     \"Hemodialysis for children with chronic kidney disease\", section on 'Malnutrition'",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Growth may be further impaired by altered growth hormone production and metabolism, and this component responds to treatment with recombinant growth hormone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27881?source=see_link\">",
"     \"Growth hormone treatment in children with chronic kidney disease and postrenal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4422322\">",
"    <span class=\"h2\">",
"     Critical illness and post-operative states",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants and children with critical illness and those who are undergoing surgery are commonly thought to be hypermetabolic and in need of specialized nutrition support. The extent of hypermetabolism varies substantially and is difficult to predict with certainty [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11529/abstract/7\">",
"     7",
"    </a>",
"    ]; it may be less common with modern techniques for anesthesia and pain control [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11529/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Overfeeding should be avoided because it increases the ventilatory work by increasing carbon dioxide production, and can induce hepatic steatosis and cholestasis, and hyperglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11529/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with critical illness should undergo nutritional assessment upon entry into the intensive care unit (ICU) to identify preexisting nutritional problems (either underweight or overweight) as well as risk factors for the development of nutritional complications (including expectations for when the patient will be able to eat, and predicted metabolic needs) due to critical illness or its therapy. A measured weight should be obtained if at all possible on admission, and periodically remeasured during the hospital stay. Serial measurements of weight are often overlooked in the ICU, but provide critical information about changes in the patient&rsquo;s nutritional and fluid status [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11529/abstract/10\">",
"     10",
"    </a>",
"    ]. Standard equations can be used to estimate energy needs, but are often unreliable, and can either underestimate or overestimate needs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11529/abstract/11\">",
"     11",
"    </a>",
"    ]. Therefore, the use of indirect calorimetry to measure energy needs has been suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11529/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Periodic reassessment of nutrition needs and monitoring of actual input is important, because energy requirements change during the course of an illness, and because the quantity of enteral feeds actually administered is often well below the intended target, due to interruptions in the feeding schedule due to intolerance or competing medical procedures, such as fasting prior to medical procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11529/abstract/5,14,15\">",
"     5,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4320479\">",
"    <span class=\"h3\">",
"     Burns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with thermal injury have increased requirements for energy and protein, which must be met to achieve optimal outcomes. Their micronutrient status is probably altered as well [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11529/abstract/5,16\">",
"     5,16",
"    </a>",
"    ]. This is due in part to a hypermetabolic response to the burn injury, which markedly increases energy needs. As an example, the metabolic rate in children with burn injuries of more than 40 percent of their body surface area increases by about 180 percent, and remained elevated at 150 percent even after full healing of the wound [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11529/abstract/17\">",
"     17",
"    </a>",
"    ]. As a result of these increased needs, nutritional support should be given to patients with moderate or severe burns (based on burn depth and surface area) within 24 to 48 hours of the injury, if the patient is stable but unable to consume sufficient calories by mouth. Nutritional management of patients with severe burns, including formula selection and equations for estimating energy needs in children, are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11401?source=see_link\">",
"     \"Nutritional demands and enteral formulas for moderate to severe burn patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hypermetabolic response to the injury also causes increased protein catabolism with muscle wasting, and peripheral insulin resistance, which leads to hyperglycemia. The prevention of hyperglycemia with intensive regimens including exogenous insulin has also been shown to improve outcomes in children with burns [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11529/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. However, maintaining a continuous insulin infusion in burn patients is difficult because of the need for frequent interruptions in their enteral feedings, with associated risks for hypoglycemia. These and other issues related to the hypermetabolic response in adults and children with burn injuries are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=see_link&amp;anchor=H28#H28\">",
"     \"Hypermetabolic response to severe burn injury: Recognition and treatment\", section on 'Insulin'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4320486\">",
"    <span class=\"h3\">",
"     Cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional management of patients with cancer is critical during active disease and during the treatment regimens. Treatment such as chemotherapy, radiation, or surgery may cause anorexia, poor oral tolerance, and inadequate intake. Energy requirements are variable depending on stress and state of catabolism, and may be impacted by tumor burden. Tube feedings for total intake or as a supplement to oral intake can be considered to support a patient during treatment and when anorexia occurs. Standard feedings can be used unless there are issues with malabsorption, in which case a semi-elemental feeding may be advantageous.",
"   </p>",
"   <p>",
"    Patients undergoing hematopoietic stem cell transplantation are particularly likely to require nutritional support. In many cases they require parenteral, rather than enteral nutrition, due to gastrointestinal dysfunction from preparative chemotherapy and radiation. These children may have lower energy needs than predicted by standard equations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11529/abstract/22\">",
"     22",
"    </a>",
"    ], so direct measurement of nutritional needs by indirect calorimetry can help target energy intake [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11529/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4320493\">",
"    <span class=\"h2\">",
"     Neuromuscular impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuromuscular disease may either decrease or increase energy requirements. As examples, children with choreoathetoid cerebral palsy (but not spastic cerebral palsy) tend to have increased energy expenditure, whereas those with Down syndrome or myelomeningocele generally have lower energy requirements than expected for their age and size. The energy requirement also may depend on the child&rsquo;s nutritional status: the resting energy expenditure (REE) of malnourished children with severe cerebral palsy tends to be lower than expected prior to a nutritional intervention, but rises to normal after supplemental feeds are begun [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11529/abstract/24\">",
"     24",
"    </a>",
"    ]. This pattern is similar to that seen in other children with malnutrition. Because of the variable energy needs of neurologically impaired children, it is important to monitor a child&rsquo;s nutritional status after beginning a nutrition intervention, and readjust energy intake as needed. &nbsp;",
"   </p>",
"   <p>",
"    Some children with neuromuscular impairment are also at risk for aspiration due to swallowing dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gastroesophageal reflux; these are important considerations when selecting the route and regimen for enteral nutrition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38632?source=see_link\">",
"     \"Aspiration due to swallowing dysfunction in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although concentrated formulas may be useful to reduce gastric volume and the risk of gastroesophageal reflux, it is also important to ensure that the patient receives sufficient fluid. Maintenance fluid requirements depend on the child&rsquo;s weight, and can be estimated using a simple equation or calculator (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?7/60/8129?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). Considerations including individual variations in water loss are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=see_link\">",
"     \"Maintenance fluid therapy in children\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4320500\">",
"    <span class=\"h1\">",
"     FORMULA SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selection of a formula for enteral feeding depends on the age of the infant or child and basic gastrointestinal and metabolic function.",
"   </p>",
"   <p>",
"    Factors informing formula selection in infants and young children include prematurity and chronological age, and the function of the gastrointestinal tract, liver, and pancreas including protein sensitivities and carbohydrate and fat malabsorption. Selection of formula may also depend on the severity of any underlying illness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    presence of critical illness (where gastrointestinal function is assumed to be impaired). &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H870146\">",
"    <span class=\"h2\">",
"     Protein source",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formulas can be categorized based on their protein source and extent, if any, of its hydrolysis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Cow&rsquo;s milk protein",
"      </strong>",
"      <strong>",
"       formulas",
"      </strong>",
"      are composed of intact, cow&rsquo;s milk-derived proteins, and are typically used for standard formulas for all ages. These can be used for enteral nutrition for most infants and children.",
"     </li>",
"     <li>",
"      <strong>",
"       Soy protein-based formulas",
"      </strong>",
"      can be used for feeding infants with galactosemia since the carbohydrate source is lactose-free, or if a vegan diet is preferred by the family since the protein source is from plants. Soy formulas are not recommended for the prevention of food allergies. Although they are often tolerated by infants with an IgE-mediated cow&rsquo;s milk allergy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40087?source=see_link&amp;anchor=H4#H4\">",
"       \"Milk allergy: Management\", section on 'Cross-reactivity to other protein sources'",
"      </a>",
"      ), they are usually not tolerated by infants with cow&rsquo;s milk protein colitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link&amp;anchor=H7335067#H7335067\">",
"       \"Food protein-induced proctitis/colitis and enteropathy of infancy\", section on 'Formula-supplemented or -fed infants'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hydrolysate (&rdquo;semi-elemental&rdquo;) formulas",
"      </strong>",
"      are made from cow&rsquo;s milk protein that is partially hydrolyzed. Although the shorted chain length of these hydrolyzed proteins makes them less likely to elicit an immunologic response in susceptible children, these formulas are not truly \"hypoallergenic\". These formulas are lactose-free and most have some percentage of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/55/14195?source=see_link\">",
"       medium chain triglycerides",
"      </a>",
"      in which can be useful in cases of fat malabsorption.",
"     </li>",
"     <li>",
"      <strong>",
"       Elemental formulas",
"      </strong>",
"      are made from free amino acids and are indicated for patients with severe cow&rsquo;s milk protein allergy or multiple food allergies or malabsorption (eg, due to short bowel syndrome). These formulas are also lactose-free and some contain medium chain fats which may enhance fat absorption.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H870153\">",
"    <span class=\"h2\">",
"     Age considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formulas are further categorized by age group. Each is designed to be nutritionally complete (ie, provide estimated needs for energy and all macro- and micronutrients) if given to the appropriate age group and in the appropriate quantity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Formulas for infants (",
"      <a class=\"graphic graphic_table graphicRef75231 \" href=\"UTD.htm?43/22/44397\">",
"       table 1",
"      </a>",
"      ), which are designed to be similar to breast milk, are typically lower in caloric density, calcium, and phosphorus compared with formulas for toddlers and children. Infant formulas need to be provided in volumes of 150 to 175",
"      <span class=\"nowrap\">",
"       mL/kg/day",
"      </span>",
"      to provide recommended requirements of energy, vitamins, and minerals (if given at standard concentrations). Younger infants or those needing catch-up growth will be on the higher end of this range. Infants who are failing to thrive may need infant formulas concentrated to 22 or 24",
"      <span class=\"nowrap\">",
"       kcal/oz",
"      </span>",
"      to ensure adequate energy, protein, and mineral intake to promote catch-up weight gain. &nbsp; &nbsp;",
"      <br/>",
"      <br/>",
"      In healthy infants older than six months of age, infant formulas are generally supplemented with complementary feedings, so they do not rely on formula alone to meet nutrient needs. On the other hand, older infants and children who are receiving the bulk of their nutrition via enteral nutrition due to medical or gastrointestinal diseases often rely on formula for all of their nutritional needs. The total fluid, energy, and macro- and micronutrient needs of these patients therefore should be reviewed serially.",
"     </li>",
"     <li>",
"      After one year of age, a variety of formulas are available, depending on the child&rsquo;s needs and some disease-specific considerations (",
"      <a class=\"graphic graphic_table graphicRef53184 graphicRef65947 \" href=\"UTD.htm?3/28/3534\">",
"       table 2A-B",
"      </a>",
"      ). For children between 1 and 10 years of age, formulas are generally designed to have higher micronutrient concentrations as compared with adult formulas. For children 10 years of age and older, formulas designed for adults usually can be used.",
"      <br/>",
"      <br/>",
"      Concentrated formulas are available in caloric densities up to 2",
"      <span class=\"nowrap\">",
"       kcal/mL,",
"      </span>",
"      and may be useful in some children with high caloric needs and low fluid tolerance. However, these formulas are typically hyperosmolar and can lead to diarrhea and dumping syndrome if infused rapidly, or to intravascular volume depletion if adequate fluids are not supplied.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15265080\">",
"    <span class=\"h2\">",
"     Specialty formulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specially designed formulas are valuable for treating specific metabolic conditions, such as phenylketonuria or other inborn errors of metabolism, or intractable seizures requiring a ketogenic diet. The formula is specific to the disease condition and affected individuals require close monitoring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/30/15850?source=see_link\">",
"     \"The ketogenic diet\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/58/35753?source=see_link\">",
"     \"Overview of phenylketonuria\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    There is less evidence to support the widespread use of formulas designed for disease conditions such as glucose intolerance, hepatic, pulmonary, or renal disease. Studies of most of these formulas in adults have not shown consistent benefit, as discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34073?source=see_link&amp;anchor=H11#H11\">",
"     \"Nutrition support in critically ill patients: Enteral nutrition\", section on 'Critical illness'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4320507\">",
"    <span class=\"h1\">",
"     NUTRITIONAL REQUIREMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When initiating enteral feeds, the target volume is calculated based on estimated needs for fluid and energy. These are only estimates, and actual needs vary substantially. Therefore, in all children on enteral feeds, weight gain and growth should be reassessed periodically and the regimen adjusted to optimize growth. The clinical goal is to achieve a growth pattern that follows along the curves of the",
"    <span class=\"nowrap\">",
"     WHO/CDC",
"    </span>",
"    growth charts. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4320777\">",
"    <span class=\"h2\">",
"     Children with healthy growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended dietary allowance (RDA) provides an estimate of the energy or protein needs that meets the needs of most healthy individuals in an age group, allowing for optimal growth for their genetic potential. Average energy requirements in healthy infants are approximately 110",
"    <span class=\"nowrap\">",
"     kcal/kg/day",
"    </span>",
"    at 1 month of age, 95",
"    <span class=\"nowrap\">",
"     kcal/kg/day",
"    </span>",
"    at 3 months of age, and 80",
"    <span class=\"nowrap\">",
"     kcal/kg/day",
"    </span>",
"    between 6 and 12 months of age (",
"    <a class=\"graphic graphic_figure graphicRef87702 \" href=\"UTD.htm?39/15/40190\">",
"     figure 1",
"    </a>",
"    ), based on estimates from the World Health Organization (WHO) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11529/abstract/25\">",
"     25",
"    </a>",
"    ]. For children three years and older, estimates prepared by the Institute of Medicine (IOM) are most commonly used, ranging from 100",
"    <span class=\"nowrap\">",
"     kcal/kg/day",
"    </span>",
"    in three-year old children to 40 to 50",
"    <span class=\"nowrap\">",
"     kcal/kg/day",
"    </span>",
"    in adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11529/abstract/26\">",
"     26",
"    </a>",
"    ]. For young children, the IOM estimates are somewhat higher than those prepared by the WHO (",
"    <a class=\"graphic graphic_table graphicRef87722 \" href=\"UTD.htm?40/48/41741\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Ranges for energy and protein needs in each age group are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef78274 \" href=\"UTD.htm?4/46/4845\">",
"     table 4",
"    </a>",
"    ); and variations of the",
"    <a class=\"external\" href=\"file://www.choosemyplate.gov/myplate/index.aspx\">",
"     estimated energy requirements (EER) based on activity level",
"    </a>",
"    are available from the United States Department of Agriculture website. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28631?source=see_link&amp;anchor=H11#H11\">",
"     \"Dietary history and recommended dietary intake in children\", section on 'Dietary Reference Intakes (DRIs)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These goals can be used to plan the initial enteral feeds for children whose growth is within a healthy range and who do not have a disorder causing hypermetabolism or malabsorption. In children with hypermetabolism or malabsorption, energy and protein needs will be increased, as discussed above (see",
"    <a class=\"local\" href=\"#H4320436\">",
"     'Disease-specific considerations'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4320785\">",
"    <span class=\"h2\">",
"     Children needing catch-up growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;If catch up growth is necessary, the energy and protein needs will be increased, and the following equations can be used to estimate needs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Energy needs",
"      <span class=\"nowrap\">",
"       (kcal/kg/day)",
"      </span>",
"      = EER for age",
"      <span class=\"nowrap\">",
"       (kcal/kg/day)",
"      </span>",
"      x ideal weight for height",
"      <span class=\"nowrap\">",
"       (kg)/actual",
"      </span>",
"      weight (kg) &nbsp; &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      Protein needs",
"      <span class=\"nowrap\">",
"       (g/kg/day)",
"      </span>",
"      = RDA for protein for age",
"      <span class=\"nowrap\">",
"       (g/kg/day)",
"      </span>",
"      x ideal weight for height",
"      <span class=\"nowrap\">",
"       (kg)/actual",
"      </span>",
"      weight (kg)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Where EER = estimated energy requirement; RDA = recommended dietary allowance. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Children with malabsorptive states such as short bowel syndrome or cystic fibrosis will likely need greater than the RDA amount of energy to support normal growth. The same situation may apply for children who are hypermetabolic, such as unrepaired cardiac defects or severe burns. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H869476\">",
"    <span class=\"h2\">",
"     Adjustments for children with obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with obesity (BMI &gt;95",
"    <sup>",
"     th",
"    </sup>",
"    percentile) requiring chronic enteral feeds, the clinical goal should be to provide energy and protein to achieve very gradual weight loss (eg, one to two",
"    <span class=\"nowrap\">",
"     pounds/month).",
"    </span>",
"    One approach is to target an energy intake about 200 kcals below the usual range for the child&rsquo;s age group (",
"    <a class=\"graphic graphic_table graphicRef78274 \" href=\"UTD.htm?4/46/4845\">",
"     table 4",
"    </a>",
"    ). The intake can then be adjusted up or down to achieve gradual weight loss. In young children with obesity admitted for intercurrent illnesses, calorie restriction to promote weight loss is probably not useful and may impede recovery from the illness. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23168346\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients on long-term enteral feeds, the adequacy of energy intake is monitored by serially measuring height and weight and plotting the results on a growth curve. For those with suboptimal growth, the caloric intake can be increased by increasing feeding volume",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    concentration. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    For these patients, we also suggest periodic assessment of routine blood chemistries (eg, electrolytes, blood urea nitrogen [BUN], calcium, phosphorus, magnesium, zinc, iron, and fat soluble vitamins) to ensure optimal nutrition. These measures are most important in patients with underlying disorders that put them at risk for malabsorption and for those with malnutrition. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4320529\">",
"    <span class=\"h1\">",
"     ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small gauge flexible feeding tubes made from silicone or polyurethane are well suited for providing enteral feeds to children. Access can be intragastric (eg, orogastric, nasogastric, or gastrostomy tubes), or transpyloric (eg, nasoduodenal, nasojejunal). Intragastric feedings are generally preferred due to their more physiologic nature, but transpyloric feedings may be selected in patients at risk for aspiration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33592?source=see_link\">",
"     \"Enteral feeding: Gastric versus post-pyloric\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are advantages and disadvantages with each access route option and method of feeding:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H869582\">",
"    <span class=\"h2\">",
"     Nasogastric or orogastric route",
"    </span>",
"    &nbsp;&mdash;&nbsp;Naso- or orogastric access can be used for infants and children who are predicted to have only short-term need for enteral feeds (eg, less than three months). In addition, they are often used as an interim measure to feed and assess tolerance of enteral feedings before placement of an ostomy for long-term enteral feeding. Placement of a nasogastric or orogastric tube does not require surgery or endoscopy, and parents can be taught how to replace the tube at home. Potential disadvantages with this route are interference with oral intake, easy dislodgement, irritation to the",
"    <span class=\"nowrap\">",
"     nasal/oral",
"    </span>",
"    area, infection, and, for older children, stigmatization with visible tube in place. The nasogastric route usually is preferred over gastrostomy for patients with biliary atresia or other causes of portal hypertension, because of the propensity to develop varices around the site of a gastrostomy. (See",
"    <a class=\"local\" href=\"#H4320450\">",
"     'Gastrointestinal disease and dysfunction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A soft, flexible feeding tube (eg, made from polyurethane or silicone) should be used if possible. Tube sizes of 4 French should be used for neonates and infants, and 8 French for children and adolescents. Smaller tubes are more comfortable for the patient, but may become clogged more quickly with formula and medication administration. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H869597\">",
"    <span class=\"h2\">",
"     Gastrostomy route",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrostomy tube (GT) feeding usually is appropriate if long-term enteral feeding is required, and they are usually easily placed laparoscopically or endoscopically. The gastrostomy can be fitted with a device that is easy to cover with clothes. Disadvantages of gastrostomy placement include local",
"    <span class=\"nowrap\">",
"     irritation/infection,",
"    </span>",
"    leaking, allergic reaction, and possible dislodgement.",
"   </p>",
"   <p>",
"    Bolus intragastric feedings are generally preferred over continuous feeds if they can be tolerated, since they provide a more normal pattern of eating and can deliver larger volumes over a shorter period of time (generally 10 to 20 minutes per bolus). If the patient can tolerate a bolus by gravity infusion, a pump is not necessary. Bolus feeds may also reduce the risk of aspiration because they are typically administered while the infant or child is awake and upright. On the other hand, the bolus method feeding might also increase the risk of pulmonary aspiration if large volumes are given. If a bolus feed is given while the child is asleep, the head of the bed should be elevated to least at a 45 degree angle to help reduce aspiration risk.",
"   </p>",
"   <p>",
"    Continuous feeding regimens are useful for infants and children who do not tolerate bolus feeds, either because of malabsorptive disease (eg, short bowel syndrome), feeding intolerance (eg, many infants with congenital heart disease), or gastroesophageal reflux with aspiration risk (eg, some children neurologic impairment). This method requires a pump, and appropriate measures to ensure freshness of the formula or breast milk in the reservoir. In addition, continuous nocturnal feeding is used for some children with a chronic illness to supplement to their daytime oral intake (eg, children with cystic fibrosis and growth failure). When feeds are given while the child is asleep, the head of the bed should be elevated, as described above for bolus feeds. Some children may have an additional surgical procedure (eg, a fundoplication) to provide additional protection against gastroesophageal reflux and aspiration. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H869606\">",
"    <span class=\"h2\">",
"     Transpyloric route",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transpyloric feedings may be required for infants and children with poor gastric emptying",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aspiration risk; they reduce but do not eliminate gastroesophageal reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11529/abstract/27\">",
"     27",
"    </a>",
"    ]. Transpyloric feeding is given through a nasojejunal (NJ) or gastrostomy-jejunal combined tube (GJT), or occasionally with a surgically placed jejunostomy tube (JT). Transpyloric feeding requires a pump and continuous infusion schedule of feedings because infusion of boluses directly into the small intestine results in dumping syndrome and is contraindicated. Small pumps are available and can be carried by the child in a backpack to allow mobility.",
"   </p>",
"   <p>",
"    For patients requiring transpyloric feeds, surgical placement of a GJT or JT is almost always preferable to use of a NJ tube. NJ tubes are helpful in the ICU setting when feeding courses are short and patient motion is minimal. Their use in ambulatory patients is notable for a number of drawbacks: the tubes are difficult to place correctly, and often require fluoroscopy to guide the tube through the pylorus and ensure appropriate tip location, with the associated risk of radiation exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H869847\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enteral nutrition consists of providing nutrients via the gastrointestinal tract, and in common usage the term usually refers to tube feeding. Enteral nutrition offers several advantages over parenteral nutrition including lower costs, beneficial effects from utilization of the gastrointestinal tract, and avoidance of the many potential complications of parenteral nutrition.",
"     </li>",
"     <li>",
"      Common indications for enteral nutrition in children fall into the following categories (which are not mutually exclusive): (see",
"      <a class=\"local\" href=\"#H4320429\">",
"       'Indications for enteral nutrition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4320436\">",
"       'Disease-specific considerations'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Decreased ability to ingest nutrients (eg, prematurity, cerebral palsy or other neurologic problems or congenital anomalies of the gastrointestinal tract)",
"     </li>",
"     <li>",
"      Inability to meet increased metabolic demands of illness (sepsis, burns or other type of critical illness; congenital heart disease or bronchopulmonary dysplasia) &nbsp;",
"     </li>",
"     <li>",
"      Altered digestion, absorption or metabolism of nutrients (short bowel syndrome, cystic fibrosis, Crohn&rsquo;s disease, some inborn errors of metabolism, chronic renal insufficiency)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Selection of a formula for enteral feeding depends on the patient&rsquo;s age, ability to tolerate intact protein, and sometimes on disease-specific considerations. Separate formulas are used for infants (",
"      <a class=\"graphic graphic_table graphicRef75231 \" href=\"UTD.htm?43/22/44397\">",
"       table 1",
"      </a>",
"      ) as compared with children (",
"      <a class=\"graphic graphic_table graphicRef53184 graphicRef65947 \" href=\"UTD.htm?3/28/3534\">",
"       table 2A-B",
"      </a>",
"      ). &nbsp;",
"     </li>",
"     <li>",
"      When initiating enteral feeds, the target volume is calculated based on estimated needs for fluids and energy. For children whose growth is within a healthy range, the recommended dietary allowance (RDA) provides an appropriate estimate of these needs, as shown in the table (",
"      <a class=\"graphic graphic_table graphicRef78274 \" href=\"UTD.htm?4/46/4845\">",
"       table 4",
"      </a>",
"      ). These estimates are then adjusted up for children needing catch-up growth or those with a hypermetabolic disease state or adjusted down for those who are overweight. (See",
"      <a class=\"local\" href=\"#H4320507\">",
"       'Nutritional requirements'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients undergoing long-term enteral feeding should be periodically reassessed by plotting serial heights and weights, and the volume of feeds should be adjusted up or down to achieve optimal growth. Serial measurements of body weight are often overlooked in critically ill patients, but are important to ensure adequate nutrition for recovery and growth. (See",
"      <a class=\"local\" href=\"#H4320507\">",
"       'Nutritional requirements'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nutritional requirements are particularly difficult to predict in patients with certain critical illnesses, including severe burn injuries or those undergoing hematopoietic stem cell transplantation. In such cases, measurement of the resting metabolic rate by indirect calorimetry provides an estimate of the patient&rsquo;s nutritional needs, and can help to avoid under- and over-feeding. (See",
"      <a class=\"local\" href=\"#H4320479\">",
"       'Burns'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4320486\">",
"       'Cancer'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11529/abstract/1\">",
"      Grummer-Strawn LM, Reinold C, Krebs NF, Centers for Disease Control and Prevention (CDC). Use of World Health Organization and CDC growth charts for children aged 0-59 months in the United States. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11529/abstract/2\">",
"      Secker DJ, Jeejeebhoy KN. Subjective Global Nutritional Assessment for children. Am J Clin Nutr 2007; 85:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11529/abstract/3\">",
"      Cunningham JJ. Body composition and nutrition support in pediatrics: what to defend and how soon to begin. Nutr Clin Pract 1995; 10:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11529/abstract/4\">",
"      Shulman RJ, Phillips S. Parenteral nutrition in infants and children. J Pediatr Gastroenterol Nutr 2003; 36:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11529/abstract/5\">",
"      Mehta NM, Duggan CP. Nutritional deficiencies during critical illness. Pediatr Clin North Am 2009; 56:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11529/abstract/6\">",
"      Varan B, Tokel K, Yilmaz G. Malnutrition and growth failure in cyanotic and acyanotic congenital heart disease with and without pulmonary hypertension. Arch Dis Child 1999; 81:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11529/abstract/7\">",
"      Mehta NM, Bechard LJ, Leavitt K, Duggan C. Cumulative energy imbalance in the pediatric intensive care unit: role of targeted indirect calorimetry. JPEN J Parenter Enteral Nutr 2009; 33:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11529/abstract/8\">",
"      Jaksic T, Shew SB, Keshen TH, et al. Do critically ill surgical neonates have increased energy expenditure? J Pediatr Surg 2001; 36:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11529/abstract/9\">",
"      Anand KJ, Hickey PR. Halothane-morphine compared with high-dose sufentanil for anesthesia and postoperative analgesia in neonatal cardiac surgery. N Engl J Med 1992; 326:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11529/abstract/10\">",
"      Mehta NM, Compher C, A.S.P.E.N. Board of Directors. A.S.P.E.N. Clinical Guidelines: nutrition support of the critically ill child. JPEN J Parenter Enteral Nutr 2009; 33:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11529/abstract/11\">",
"      Mehta NM, Costello JM, Bechard LJ, et al. Resting energy expenditure after Fontan surgery in children with single-ventricle heart defects. JPEN J Parenter Enteral Nutr 2012; 36:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11529/abstract/12\">",
"      Mehta NM, Bechard LJ, Leavitt K, Duggan C. Severe weight loss and hypermetabolic paroxysmal dysautonomia following hypoxic ischemic brain injury: the role of indirect calorimetry in the intensive care unit. JPEN J Parenter Enteral Nutr 2008; 32:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11529/abstract/13\">",
"      Smallwood CD, Mehta NM. Accuracy of abbreviated indirect calorimetry protocols for energy expenditure measurement in critically ill children. JPEN J Parenter Enteral Nutr 2012; 36:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11529/abstract/14\">",
"      de Neef M, Geukers VG, Dral A, et al. Nutritional goals, prescription and delivery in a pediatric intensive care unit. Clin Nutr 2008; 27:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11529/abstract/15\">",
"      Mehta NM, Bechard LJ, Cahill N, et al. Nutritional practices and their relationship to clinical outcomes in critically ill children--an international multicenter cohort study*. Crit Care Med 2012; 40:2204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11529/abstract/16\">",
"      Traber MG, Leonard SW, Traber DL, et al. &alpha;-Tocopherol adipose tissue stores are depleted after burn injury in pediatric patients. Am J Clin Nutr 2010; 92:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11529/abstract/17\">",
"      Hart DW, Wolf SE, Mlcak R, et al. Persistence of muscle catabolism after severe burn. Surgery 2000; 128:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11529/abstract/18\">",
"      Thomas SJ, Morimoto K, Herndon DN, et al. The effect of prolonged euglycemic hyperinsulinemia on lean body mass after severe burn. Surgery 2002; 132:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11529/abstract/19\">",
"      Herndon DN, Tompkins RG. Support of the metabolic response to burn injury. Lancet 2004; 363:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11529/abstract/20\">",
"      Fram RY, Cree MG, Wolfe RR, et al. Intensive insulin therapy improves insulin sensitivity and mitochondrial function in severely burned children. Crit Care Med 2010; 38:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11529/abstract/21\">",
"      Jeschke MG, Kulp GA, Kraft R, et al. Intensive insulin therapy in severely burned pediatric patients: a prospective randomized trial. Am J Respir Crit Care Med 2010; 182:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11529/abstract/22\">",
"      Duggan C, Bechard L, Donovan K, et al. Changes in resting energy expenditure among children undergoing allogeneic stem cell transplantation. Am J Clin Nutr 2003; 78:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11529/abstract/23\">",
"      Duro D, Bechard LJ, Feldman HA, et al. Weekly measurements accurately represent trends in resting energy expenditure in children undergoing hematopoietic stem cell transplantation. JPEN J Parenter Enteral Nutr 2008; 32:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11529/abstract/24\">",
"      Arrowsmith FE, Allen JR, Gaskin KJ, et al. Nutritional rehabilitation increases the resting energy expenditure of malnourished children with severe cerebral palsy. Dev Med Child Neurol 2012; 54:170.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Agriculture Organization of the United Nations (FAO), World Health Organization (WHO) and United Nations University (UNU): Human Energy Requirements. Chapter 2: Energy requirements of infants from birth to 12 months. Available at: file://www.fao.org/docrep/007/y5686e/y5686e05.htm (Accessed on January 21, 2013).",
"    </li>",
"    <li>",
"     DIETARY REFERENCE INTAKES FOR ENERGY, Institute of Medicine, 2005. Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids (macronutrients), 2005, chapter 5. Available at: file://fnic.nal.usda.gov/dietary-guidance/dri-reports/energy-carbohydrate-fiber-fat-fatty-acids-cholesterol-protein-and-amino#overlay-context=dietary-guidance/dietary-reference-intakes/dri-reports (Accessed on January 30, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11529/abstract/27\">",
"      Rosen R, Hart K, Warlaumont M. Incidence of gastroesophageal reflux during transpyloric feeds. J Pediatr Gastroenterol Nutr 2011; 52:532.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15643 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-197.136.42.3-9715D97815-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_16_11529=[""].join("\n");
var outline_f11_16_11529=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H869847\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4320415\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4320422\">",
"      NUTRITIONAL ASSESSMENT IN CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4320429\">",
"      INDICATIONS FOR ENTERAL NUTRITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8040962\">",
"      Decreased ability to ingest nutrients by mouth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8040969\">",
"      Inability to meet increased metabolic demands through oral nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8040976\">",
"      Altered absorption or digestion requiring modification of dietary intake",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4320436\">",
"      DISEASE-SPECIFIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4320443\">",
"      Cardiorespiratory diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4320450\">",
"      Gastrointestinal disease and dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4422335\">",
"      Renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4422322\">",
"      Critical illness and post-operative states",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4320479\">",
"      - Burns",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4320486\">",
"      - Cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4320493\">",
"      Neuromuscular impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4320500\">",
"      FORMULA SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H870146\">",
"      Protein source",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H870153\">",
"      Age considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15265080\">",
"      Specialty formulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4320507\">",
"      NUTRITIONAL REQUIREMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4320777\">",
"      Children with healthy growth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4320785\">",
"      Children needing catch-up growth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H869476\">",
"      Adjustments for children with obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23168346\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4320529\">",
"      ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H869582\">",
"      Nasogastric or orogastric route",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H869597\">",
"      Gastrostomy route",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H869606\">",
"      Transpyloric route",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H869847\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/15643\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/15643|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/15/40190\" title=\"figure 1\">",
"      Energy requirements of infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/15643|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/22/44397\" title=\"table 1\">",
"      Selecting infant formulas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/33/12829\" title=\"table 2A\">",
"      Formula selection I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/54/16236\" title=\"table 2B\">",
"      Formula selection II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/48/41741\" title=\"table 3\">",
"      Estimates of energy requirements for children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/46/4845\" title=\"table 4\">",
"      DRI selected nutrients children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?7/60/8129?source=related_link\" title=\"calculator 1\">",
"      Calculator: Maintenance fluid calculation for children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/8/19593?source=related_link\">",
"      Approach to enteral nutrition in the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38632?source=related_link\">",
"      Aspiration due to swallowing dysfunction in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39929?source=related_link\">",
"      Biliary atresia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/24/15754?source=related_link\">",
"      Cystic fibrosis: Nutritional issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43048?source=related_link\">",
"      Diagnosis and initial management of cyanotic heart disease in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28631?source=related_link\">",
"      Dietary history and recommended dietary intake in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33592?source=related_link\">",
"      Enteral feeding: Gastric versus post-pyloric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=related_link\">",
"      Food protein-induced proctitis/colitis and enteropathy of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2794?source=related_link\">",
"      Growth failure and poor weight gain in children with inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27881?source=related_link\">",
"      Growth hormone treatment in children with chronic kidney disease and postrenal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23912?source=related_link\">",
"      Growth management in preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9242?source=related_link\">",
"      Hemodialysis for children with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=related_link\">",
"      Hypermetabolic response to severe burn injury: Recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=related_link\">",
"      Maintenance fluid therapy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32248?source=related_link\">",
"      Malnutrition in developing countries: Clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/55/34680?source=related_link\">",
"      Management of isolated ventricular septal defects in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26778?source=related_link\">",
"      Management of the short bowel syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/38/6760?source=related_link\">",
"      Measurement of body composition in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31976?source=related_link\">",
"      Measurement of growth in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40087?source=related_link\">",
"      Milk allergy: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34073?source=related_link\">",
"      Nutrition support in critically ill patients: Enteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11401?source=related_link\">",
"      Nutritional demands and enteral formulas for moderate to severe burn patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/58/35753?source=related_link\">",
"      Overview of phenylketonuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41722?source=related_link\">",
"      Overview of the management of Crohn's disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=related_link\">",
"      Overview of the management of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18730?source=related_link\">",
"      Parenteral nutrition-associated liver disease in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/30/15850?source=related_link\">",
"      The ketogenic diet",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_16_11530="Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)";
var content_f11_16_11530=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/16/11530/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/16/11530/contributors\">",
"     Martin Dichgans, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/16/11530/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/16/11530/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/16/11530/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/16/11530/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/16/11530/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an autosomal dominantly inherited angiopathy that, in the 1990s, was shown to be caused by mutations in the NOTCH3 gene on chromosome 19 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/1\">",
"     1",
"    </a>",
"    ]. CADASIL is now recognized as an important cause of stroke in the young [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stroke and vascular cognitive impairment remain the main causes of morbidity and mortality in patients with CADASIL. Previous descriptions of families with \"hereditary multi-infarct dementia,\" \"chronic familial vascular encephalopathy,\" and \"familial subcortical dementia\" represent early reports of the same condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Molecular mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NOTCH3 gene (MIM 600276) on chromosome 19p13.2-p13.1 is one of four mammalian homologs of the Drosophila NOTCH gene [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/4\">",
"     4",
"    </a>",
"    ]. NOTCH genes code for large transmembrane receptors involved in cell fate decisions during embryonic development [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/5\">",
"     5",
"    </a>",
"    ]. The protein product Notch3 is critical for vascular smooth muscle cell (VSMC) differentiation and vascular development [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/6\">",
"     6",
"    </a>",
"    ]. In adults, expression of NOTCH3 is largely restricted to VSMCs.",
"   </p>",
"   <p>",
"    Like all Notch receptors, the Notch3 receptor is proteolytically processed in the trans-Golgi network as it traffics from the endoplasmic reticulum to the plasma membrane. Proteolytic cleavage results in a large extracellular fragment and a small intracellular fragment that contains the transmembrane region.",
"   </p>",
"   <p>",
"    In CADASIL (MIM #125310), the extracellular domain of the Notch3 receptor accumulates within blood vessels. Accumulation takes place at the cytoplasmic membrane of VSMCs and pericytes in close vicinity to the granular osmiophilic deposits that characterize the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Apart from its role in vessel development, the Notch3 receptor seems to be involved in vascular remodeling following injury [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. However, the mechanisms by which NOTCH3 mutations eventually become pathogenic are still incompletely understood [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. An interesting observation potentially relating to the frequent occurrence of migraine with aura in CADASIL is that transgenic mice expressing a vascular Notch3 mutation show an enhanced susceptibility to experimentally induced cortical spreading depression [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Genotype-phenotype correlations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several reports on associations between specific NOTCH3 mutations and particular disease manifestations or accelerated disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/2,13-16\">",
"     2,13-16",
"    </a>",
"    ]. However, none of these associations has been firmly established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hemodynamic changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although CADASIL is a generalized angiopathy, the vascular complications are largely limited to the brain. This discrepancy might, in part, be related to the predominant involvement of leptomeningeal and long penetrating arteries of the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/17\">",
"     17",
"    </a>",
"    ]. Morphometric studies have revealed a significant reduction of the internal diameter of small penetrating arteries and an increased thickness of the arteriolar wall in both the gray and white matter of the brain. Another potential factor contributing to the preferential involvement of the brain is the anatomy of the blood brain barrier [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occlusion of cerebral blood vessels is a rare finding in most pathologic studies of patients with CADASIL, suggesting that functional hemodynamic changes may be important. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemodynamic studies in humans have been conflicting. As examples, some reports found impaired cerebral vasoreactivity [",
"      <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/20,21\">",
"       20,21",
"      </a>",
"      ], whereas such changes were not found by other groups [",
"      <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/22,23\">",
"       22,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Studies in CADASIL transgenic mice have found an impaired vasomotor response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      and hypercapnia [",
"      <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/24\">",
"       24",
"      </a>",
"      ], which would be in line with the initial observations in patients [",
"      <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. CADASIL transgenic mice also had evidence of disturbed autoregulation, an altered response to flow-induced vasodilation, changes in pressure-induced myogenic tone, a reduced caliber of brain arteries, and a substantial progressive rarefaction of capillaries in the white matter of the brain [",
"      <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/24-26\">",
"       24-26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most autopsy studies have been carried out in patients with advanced disease. Macroscopic examination of the brain reveals rarefaction of the subcortical white matter with periventricular preference [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/18\">",
"     18",
"    </a>",
"    ]. Another consistent finding is lacunar infarcts predominantly within the basal ganglia, thalamus, and brainstem, particularly in the pons. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4026?source=see_link\">",
"     \"Lacunar infarcts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Histologically, various degrees of demyelination, axonal loss, enlargement of the extracellular space, and mild astrocytic gliosis are found; these findings are compatible with chronic ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/18\">",
"     18",
"    </a>",
"    ]. In a neuropathologic study of four patients who died from complications of CADASIL, neuronal apoptosis was seen in layers 3 and 5 of the cerebral cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The underlying vascular lesion is a unique nonarteriosclerotic, amyloid-negative angiopathy involving small arteries (100 to 400 microns in diameter) and capillaries, primarily in the brain but also in other organs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/18\">",
"     18",
"    </a>",
"    ]. The morphologic hallmark on electron microscopy is the presence of electron-dense granular osmiophilic material (GOM) within the arterial media surrounding the smooth muscle cells. These ultrastructural GOM deposits have not been characterized biochemically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;CADASIL has been reported worldwide. Based upon registers from single referral centers and regional databases, the prevalence of mutation carriers has been estimated at 0.8 to 2 per 100,000 individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with CADASIL usually present with one or more of the following four manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/3,31,32\">",
"     3,31,32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ischemic episodes",
"     </li>",
"     <li>",
"      Cognitive deficits",
"     </li>",
"     <li>",
"      Migraine with aura",
"     </li>",
"     <li>",
"      Psychiatric disturbances",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less common manifestations include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      \"CADASIL coma\" (an acute reversible encephalopathy) in up to 10 percent of cases; the underlying mechanisms are not fully understood [",
"      <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/33-35\">",
"       33-35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Seizures in 5 to 10 percent of patients",
"     </li>",
"     <li>",
"      Spinal cord signs [",
"      <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/36\">",
"       36",
"      </a>",
"      ] and spinal cord infarcts [",
"      <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/37,38\">",
"       37,38",
"      </a>",
"      ] in case reports",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intracerebral hemorrhage has been rarely described in patients with CADASIL [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/39\">",
"     39",
"    </a>",
"    ]. However, an exception is a case series of 20 consecutive symptomatic patients with CADASIL from Korea [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/40\">",
"     40",
"    </a>",
"    ]. High susceptibility brain MRI sequences (T2*-weighted images) detected seven intracerebral hemorrhages in five patients (25 percent), and intracerebral hemorrhage was the presenting sign in two (10 percent). Hemorrhages were located in the basal ganglia, thalamus, cerebellum, and parietal lobe; their largest diameters ranged from 1.2 to 2.8 cm.",
"   </p>",
"   <p>",
"    Evidence of possible cardiac involvement in CADASIL is conflicting. In different small series, NOTCH3 mutation carriers had an increased risk of early myocardial infarction compared to noncarriers in the same family [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/41\">",
"     41",
"    </a>",
"    ], while a later study found no electrocardiographic evidence of myocardial infarction or ischemia patients with CADASIL who had no cardiac risk factors other than hypercholesterolemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Age at onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of symptomatic disease in patients with CADASIL typically occurs in adulthood. However, brain lesions on MRI have been detected in some asymptomatic children with a family history of CADASIL [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. In addition, there are case reports of adolescents with migraine, cognitive deficits and neuroimaging features of CADASIL [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. The earliest known case of symptomatic CADASIL is an 8-year-old boy who presented with behavioral and attentional problems [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/47\">",
"     47",
"    </a>",
"    ]. Brain MRI showed multiple foci of increased T2 signal on brain MRI and genetic sequencing identified a NOTCH3 mutation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Migraine with aura",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine with aura occurs in about 30 percent of CADASIL cases and is usually an early sign [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/31,32,48\">",
"     31,32,48",
"    </a>",
"    ]. The average age at onset of migraine with aura is approximately 30 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Aura symptoms tend to involve the visual and sensory system. Some patients develop symptoms of hemiplegic migraine, basilar migraine, or isolated aura, which may be difficult to differentiate from ischemic episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/31,49\">",
"     31,49",
"    </a>",
"    ]. The frequency of migraine attacks seems to decrease after the first stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/31\">",
"     31",
"    </a>",
"    ]. At younger ages (&le;50 years), migraine with aura in patients with CADASIL may be more prevalent in women than in men [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Ischemic stroke and TIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic stroke and transient ischemic attacks (TIA) are frequent manifestations of CADASIL, occurring in about 85 percent of symptomatic individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In a large retrospective study, the age at onset for ischemic stroke ranged from 19 to 67 years, and the median age for ischemic stroke onset in men and women was 51 and 53 years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/2\">",
"     2",
"    </a>",
"    ]. At younger ages (&le;50 years), ischemic stroke in patients with CADASIL may be more prevalent in men than in women [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In many cases, ischemic episodes present as a classic lacunar syndrome (pure motor stroke, ataxic-hemiparesis, dysarthria&ndash;clumsy hand syndrome, pure sensory stroke, sensorimotor stroke), but other lacunar syndromes (brainstem or hemispheric) are also observed. Strokes are often recurrent, leading to severe disability with gait disturbance, urinary incontinence, and pseudobulbar palsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4026?source=see_link\">",
"     \"Lacunar infarcts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Strokes involving the territory of a large artery have occasionally been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/52\">",
"     52",
"    </a>",
"    ], and a study that evaluated 13 patients with CADASIL found angiographic large artery stenosis in five (38 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/53\">",
"     53",
"    </a>",
"    ]. However, these observations may be coincidental.",
"   </p>",
"   <p>",
"    The presence of conventional stroke risk factors may exacerbate disease severity in CADASIL. In a study of 200 patients with CADASIL, the risk of stroke was significantly higher in those with hypertension (odds ratio [OR] 2.57, 95% CI 1.29-5.14) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/35\">",
"     35",
"    </a>",
"    ]. In addition, the risk of stroke increased with pack-years of smoking (OR 1.07, 95% CI 1.03-1.11).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cognitive deficits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive deficits are the second most frequent feature, observed in about 60 percent of symptomatic patients with CADASIL. Approximately 75 percent of the mutation carriers eventually develop dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/2,31\">",
"     2,31",
"    </a>",
"    ]. Lacunar lesion volume and global brain atrophy (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Brain atrophy'",
"    </a>",
"    below) on brain MRI as well as older age appear to be independent predictors of cognitive impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Another important aspect is lesion location, particularly involvement of frontal-subcortical circuits [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cognitive syndrome in CADASIL is characterized by deficits in multiple domains [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/57\">",
"     57",
"    </a>",
"    ]. Early impairment of executive function is followed by deterioration in other cognitive domains with aging [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. In most cases, cognitive decline is slowly progressive with additional stepwise deterioration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/60\">",
"     60",
"    </a>",
"    ]. Neuropsychologic testing usually shows pronounced deficits in executive function, cognitive processing speed, and verbal fluency [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/61\">",
"     61",
"    </a>",
"    ]. Cognitive dysfunction is accompanied by a narrowing of the field of interest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Neuropsychiatric symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mood disorders occur in about 25 to 30 percent of patients with CADASIL [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/31,32,62\">",
"     31,32,62",
"    </a>",
"    ]. Many patients develop adjustment disorder or moderate depression, but major depression is also seen. Other manifestations include bipolar disorder, panic disorder, hallucinatory syndrome, and delusional episodes. Rarely, CADASIL presents with a picture of schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Apathy is another common problem in CADASIL [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/64\">",
"     64",
"    </a>",
"    ], and appears to be more common in men than women with the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/51\">",
"     51",
"    </a>",
"    ]. Apathy has been defined as a primary loss of motivation, characterized by diminished speech, motor activity, and emotional expression. This definition of apathy is similar to that of abulia, defined as a loss of the impulse, will, or motivation to think, speak, and act. Diminished motivation is the key concept in both apathy and abulia. Although apathy frequently occurs with depression, apathy can develop in the absence of depression.",
"   </p>",
"   <p>",
"    In a prospective cohort study of 132 patients with CADASIL, apathy was present in 54 (41 percent), similar to the frequencies of depression, disturbed sleep, and irritability (46, 45, and 43 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     CADASIL and pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Affected women with CADASIL may develop complications during pregnancy. In a retrospective analysis, 12 of 25 mothers (48 percent) developed neurologic symptoms in 40 percent of their pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/65\">",
"     65",
"    </a>",
"    ]. Complications included transient ischemic episodes, migraine, and preeclampsia-like symptoms. In the majority of cases, these complications were the initial disease manifestation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical progression in CADASIL tends to occur with the sequential development of migraine with aura around age 30, TIAs, ischemic strokes and mood disorders between 40 and 60 years, dementia between 50 and 60 years, and gait difficulty at approximately 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/3,31,32,49\">",
"     3,31,32,49",
"    </a>",
"    ]. However, the overall course of CADASIL is highly variable even within families. Some patients remain asymptomatic until their seventies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/2\">",
"     2",
"    </a>",
"    ]. Onset of symptomatic disease in childhood has been reported. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Age at onset'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Early onset does not necessarily predict rapid progression. In a review of 102 patients from 29 families, the duration from onset to death varied from 3 to 43 years, with a mean of 23 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective analysis of 411 patients with CADASIL, the median age at death was 65 years in men and 71 years in women [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     NEUROIMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain magnetic resonance imaging (MRI) is the most useful imaging method to demonstrate the radiologic features of CADASIL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI of the brain shows two major types of abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small circumscribed regions that are isointense to cerebrospinal fluid (CSF) on T1- and T2-weighted images. Most of these lesions are consistent with lacunar infarcts in terms of their size, shape, and location.",
"     </li>",
"     <li>",
"      Less well demarcated T2-hyperintensities of variable size that may show different degrees of hypointensity on T1-weighted images but are clearly distinct from CSF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The majority of these lesions are located in the subcortical white matter (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60844 \" href=\"UTD.htm?38/59/39859\">",
"     image 1",
"    </a>",
"    ), but similar lesions may be seen in other brain regions, including the brainstem and subcortical gray matter [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The onset of MRI-visible lesions and the rate of lesion progression are variable [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/32,68,69\">",
"     32,68,69",
"    </a>",
"    ], but by age 35 years all mutation carriers have developed MRI lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/32\">",
"     32",
"    </a>",
"    ]. Small irregular T2-hyperintensities involving the periventricular and deep white matter are usually the first sign in younger individuals.",
"   </p>",
"   <p>",
"    The following MRI signs may help to identify patients with CADASIL:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Temporal lobe and external capsule hyperintensities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior temporal lobe (temporal pole) white matter hyperintensities seen on T2-weighted sequences (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81669 \" href=\"UTD.htm?29/36/30278\">",
"     image 2",
"    </a>",
"    ) are found in about 90 percent of patients with CADASIL, whereas such lesions are uncommon in sporadic small vessel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/67,70\">",
"     67,70",
"    </a>",
"    ]. External capsule and corpus callosum hyperintensities seen on T2-weighted sequences are also characteristic findings [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Subcortical lacunar lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcortical lacunar lesions are linearly arranged groups of rounded circumscribed lesions that are just below the cortex at the gray-white matter junction with a signal intensity identical to CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/71\">",
"     71",
"    </a>",
"    ]. These lacunar lesions are very small and are best differentiated from surrounding white matter hyperintensity with fluid-attenuated inversion recovery (FLAIR) sequences [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Cerebral microbleeds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral microbleeds (also known as microhemorrhages) have been reported in 31 to 69 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/13,73,74\">",
"     13,73,74",
"    </a>",
"    ]. Microbleeds are small, 2 mm to 5 mm focal or multifocal areas of hemosiderin deposition and are the remnants of subclinical leaks of blood. They are best detected as small, rounded dark lesions on gradient echo or T2*-weighted MRI images that are sensitive to iron. Microbleeds are not specific for CADASIL since they are also found in patients with other types of small vessel disease.",
"   </p>",
"   <p>",
"    In a multicenter cohort study that evaluated 147 patients with CADASIL, the presence of cerebral microbleeds was independently associated with increased blood pressure, hemoglobin A1C levels, lacunar infarct volume, and the extent of white matter hyperintensities [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/74\">",
"     74",
"    </a>",
"    ]. In addition, the number of cerebral microbleeds was independently associated with poor functional outcome.",
"   </p>",
"   <p>",
"    These findings suggest that cerebral microbleeds may play a role in the neurologic deterioration seen over the course of the disease, and further suggest that treatment of elevated blood pressure and hyperglycemia may be beneficial for slowing functional decline related to CADASIL [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Brain atrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain atrophy as measured on MRI is another important feature of CADASIL. Brain atrophy may be due in part to secondary neurodegeneration of cortical regions caused by ischemic lesions in subcortical regions that disrupt connecting fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/75\">",
"     75",
"    </a>",
"    ]. In a prospective longitudinal cohort study of 76 patients with CADASIL, brain atrophy was significantly correlated with measures of disability and cognitive impairment both at baseline and follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/55\">",
"     55",
"    </a>",
"    ]. Age and male sex were independent risk factors for brain atrophy at baseline, while age and systolic blood pressure predicted change (loss) in brain volume over time.",
"   </p>",
"   <p>",
"    In contrast to the loss of overall brain volume, brain lesion volume on T2-weighted MRI did not correlate with changes in clinical measures over time [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/55,76\">",
"     55,76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional angiography is not contributory and potentially harmful, as patients with CADASIL appear to have a high risk of developing angiographic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Head CT may show lacunar infarctions and leukoaraiosis (reflecting white matter changes) but is less sensitive than MRI.",
"   </p>",
"   <p>",
"    Perfusion MRI, Doppler sonography, and nuclear medicine techniques may show reductions of cerebral blood flow, mean flow velocity, cerebral blood volume, and cerebral metabolism, but are less helpful in establishing the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/20,78,79\">",
"     20,78,79",
"    </a>",
"    ]. Postmortem high-field MRI at 7 Tesla has revealed small intracortical infarcts in a patient with CADASIL [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/80\">",
"     80",
"    </a>",
"    ]. Cortical involvement also has been reported in other patients with sporadic small vessel disease and may be clinically important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CADASIL is usually suspected when there is a positive family history for stroke or dementia in patients who have typical clinical signs and findings on brain MRI. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical features'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H15\">",
"     'Neuroimaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In order to firmly establish a diagnosis of CADASIL, one or both of the following is required:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Documentation of a typical NOTCH3 mutation by genetic analysis",
"     </li>",
"     <li>",
"      Documentation of characteristic ultrastructural deposits within small blood vessels by skin biopsy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There have been efforts to define screening scales for CADASIL [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/81\">",
"     81",
"    </a>",
"    ]. However, the utility of these scales remains to be confirmed in other populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Genetic screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 80 different mutations have been reported in patients with CADASIL from all over the world [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/82\">",
"     82",
"    </a>",
"    ]. All described mutations are located in the extracellular region of the Notch3 transmembrane receptor within epidermal growth factor (EGF)-like repeat domains. The mutational spectrum includes missense mutations, splice site mutations, and small in-frame deletions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/82,83\">",
"     82,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 95 percent of patients have missense mutations. Some mutations are particularly prevalent, but many families have private mutations. Mutations show a highly stereotyped nature since all involve cysteine residues. The usual number of six cysteine residues within wild type EGF-like repeat domains is changed toward an odd number.",
"   </p>",
"   <p>",
"    There have been single reports of atypical \"mutations\" not involving cysteine residues [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/84\">",
"     84",
"    </a>",
"    ]. However, there is no experimental evidence to demonstrate the pathogenicity of these sequence variants, which may represent rare polymorphisms.",
"   </p>",
"   <p>",
"    CADASIL mutations are strongly clustered at the N-terminus; about 60 percent of mutations are located in exon 4 and about 85 percent in exons 2 to 6, thereby enabling targeted screening strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/82\">",
"     82",
"    </a>",
"    ]. Apart from establishing the diagnosis, identification of the mutation is critical for genetic counseling and testing of relatives at risk. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Screening asymptomatic family members'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Genetic screening does not detect all patients with CADASIL. In up to 4 percent of patients, sequencing of all exons encoding EGF&ndash;like domains fails to identify a mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/82\">",
"     82",
"    </a>",
"    ]. As a result, skin biopsy is indicated if genetic testing is negative when there is a high index of clinical suspicion for the diagnosis of CADASIL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Skin biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The angiopathy in CADASIL is characterized by two main features, which are highly specific for this condition:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Granular osmiophilic material (GOM) within the vascular basal lamina of arteries, arterioles, and precapillaries on electron microscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/85-87\">",
"       85-87",
"      </a>",
"      ]. The deposits are typically located at the surface of vascular smooth muscle cells.",
"     </li>",
"     <li>",
"      Deposition of the extracellular domain of the Notch3 receptor in the vascular media of arteries and arterioles [",
"      <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/88\">",
"       88",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These changes are present in all organs, enabling a firm diagnosis by biopsy. The sensitivity and specificity of skin biopsy with subsequent ultrastructural examination has not been formally addressed. According to the author's experience, the specificity of typical GOM deposits is 100 percent. The sensitivity is less than 100 percent and largely depends upon the quality of the sample and the number of available arterioles and arteries. We usually request investigation of three arteries or arterioles before claiming a biopsy \"negative.\"",
"   </p>",
"   <p>",
"    The diagnostic value of Notch3 immunostaining is less clear [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. In one series, the sensitivity was less than 90 percent with incomplete specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/89\">",
"     89",
"    </a>",
"    ]. In addition, the respective antibody has not been approved for diagnostic purposes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific disease-modifying treatment for CADASIL, and only limited information is available regarding management of the major manifestations of the disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Ischemic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute transient ischemic attack (TIA) and acute stroke in patients with CADASIL are managed following the general principles of stroke medicine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10426?source=see_link\">",
"     \"Initial evaluation and management of transient ischemic attack and minor stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For secondary stroke prevention, we suggest that patients with CADASIL be treated with all available risk reduction strategies, although specific evidence of effectiveness for CADASIL is lacking. &nbsp;Currently viable stroke prevention strategies include blood pressure reduction, statins, and antiplatelet therapy. In addition, smoking cessation, limited alcohol consumption, weight control, regular aerobic physical activity, and a diet that is rich in fruits, vegetables, and low-fat dairy products are suggested. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=see_link&amp;anchor=H32#H32\">",
"     \"Secondary prevention of stroke: Risk factor reduction\", section on 'Recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-term management includes low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in patients who have experienced an ischemic attack and who tolerate the drug. There are no data to support the use of oral anticoagulants, which may put patients at an unnecessarily high risk of developing complications [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/13,39,73\">",
"     13,39,73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=see_link\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although there are no studies of blood pressure control in CADASIL, hypertension may be a risk factor for ischemic stroke, progression of brain atrophy and the presence of cerebral microbleeds. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Brain atrophy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H19\">",
"     'Cerebral microbleeds'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Thus, treatment of hypertension may have an additional benefit in patients with CADASIL. We suggest measures to control blood pressure for all patients with CADASIL who have elevated systolic blood pressure. Treatment of hypertension for secondary stroke prevention is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17305?source=see_link\">",
"     \"Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarly, although there is no evidence that strict glucose control can slow CADASIL progression, elevated hemoglobin A1C (A1C) levels may be a risk factor for the presence of cerebral microbleeds. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Cerebral microbleeds'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Thus, glucose control may also have an additional benefit in patients with CADASIL, and we suggest measures to normalize glycemia and A1C levels in patients with elevated A1C levels. The target A1C value should be 7.0 percent or lower for most patients. The goal should be set somewhat higher for older patients and those with a limited life expectancy in whom the risk of hypoglycemia may outweigh the potential benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=see_link\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with elevated lipids, the use of statins is suggested because of their beneficial effects for patients with atherosclerotic arterial disease, and because of experimental evidence suggesting they have neuroprotective effects [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/3,90\">",
"     3,90",
"    </a>",
"    ]. The treatment of dyslipidemia for secondary stroke prevention is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=see_link&amp;anchor=H10#H10\">",
"     \"Secondary prevention of stroke: Risk factor reduction\", section on 'Dyslipidemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Symptomatic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specific management of CADASIL focuses on the control of symptoms such as headache, depression, and urinary incontinence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"     \"Treatment of resistant depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link\">",
"     \"Treatment of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Emotional lability (pseudobulbar affect) with pathologic crying and laughing may respond to selective serotonin reuptake inhibitors (eg, a single evening dose of 100 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"       fluvoxamine",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Migraine attacks can be treated with nonsteroidal antiinflammatory drugs (NSAIDs). Triptans are relatively contraindicated in patients with CADASIL based upon the theoretical concern of increased stroke risk due to vasospasm. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21194?source=see_link\">",
"       \"Acute treatment of migraine in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Since the attack frequency of migraine with aura is low in most patients with CADASIL, few require prophylactic treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/3\">",
"       3",
"      </a>",
"      ]. For those who do, anecdotal evidence suggests that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      (250 mg per day) may be beneficial [",
"      <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/92,93\">",
"       92,93",
"      </a>",
"      ]. Standard prophylactic regimens for migraine can also be used. These are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link\">",
"       \"Preventive treatment of migraine in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When oral hydration and feeding become insufficient, the patient should receive additional tube feeding. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17000?source=see_link\">",
"       \"Diagnosis and treatment of oropharyngeal dysphagia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Screening asymptomatic family members",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic family members should receive genetic counseling prior to any procedures, such as brain MRI, which might detect subclinical signs of CADASIL.",
"   </p>",
"   <p>",
"    Predictive genetic testing should be carried out according to published guidelines dealing with ethical, legal, and psychosocial issues in other late-onset neurologic conditions for which no disease-modifying treatment is available [",
"    <a class=\"abstract\" href=\"UTD.htm?11/16/11530/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. Asymptomatic children should not be tested, while adults at risk should be referred to a genetic counselor for an educational meeting. Pre- and post-test counseling should be performed irrespective of the result of the test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an autosomal dominantly inherited angiopathy caused by mutations in the NOTCH3 gene.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The underlying vascular lesion in CADASIL is a nonatherosclerotic angiopathy involving small arteries and capillaries, primarily in the brain, characterized by the presence of electron-dense granular osmiophilic material (GOM) within the arterial media surrounding the smooth muscle cells. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major clinical manifestations of CADASIL are TIA and ischemic stroke predominately involving small vessels, cognitive deficits with early executive dysfunction, migraine with aura, and neuropsychiatric disturbances. Stroke and vascular cognitive impairment are the main causes of morbidity and mortality. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Brain MRI shows lacunar infarcts and less well demarcated T2-hyperintensities primarily located in the subcortical white matter, but also in the brainstem and subcortical gray matter. White matter T2 hyperintensities in the anterior temporal lobe and external capsule are additional features suggestive of CADASIL. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Magnetic resonance imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical course of CADASIL is highly variable. The duration from onset to death varies between 3 to 43 years with a mean of 23 years, while the median age at death is 65 years in men and 71 years in women. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CADASIL is suspected based on a combination of typical clinical signs, typical findings on brain MRI images, and a positive family history for stroke or dementia. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Magnetic resonance imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of CADASIL is established by genetic analysis with documentation of a typical NOTCH3 mutation, or by skin biopsy showing granular osmiophilic material (GOM) within small blood vessels. Skin biopsy is indicated if genetic testing is negative. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no specific disease-modifying treatment for CADASIL. For patients with CADASIL who are symptomatic with ischemic stroke or TIA, we suggest antiplatelet therapy for secondary stroke prevention (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, there are no data establishing that antiplatelet therapy is effective for preventing stroke related to CADASIL. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=see_link\">",
"       \"Antiplatelet therapy for secondary prevention of stroke\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with CADASIL who have elevated systolic blood pressure, we suggest blood pressure control (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Ischemic manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with CADASIL who have elevated hemoglobin A1C (A1C) levels, we suggest measures to normalize glycemia and A1C levels (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The target A1C value should be 7.0 percent or lower for most patients. The target should be set somewhat higher for older patients and those with a limited life expectancy, in whom the risk of hypoglycemia may outweigh the potential benefit. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Neuroimaging'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Ischemic manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with CADASIL who have dyslipidemia, we suggest treatment with statins (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Ischemic manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of CADASIL otherwise focuses on the control of symptoms such as headache, depression, and urinary incontinence. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/1\">",
"      Joutel A, Corpechot C, Ducros A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996; 383:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/2\">",
"      Opherk C, Peters N, Herzog J, et al. Long-term prognosis and causes of death in CADASIL: a retrospective study in 411 patients. Brain 2004; 127:2533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/3\">",
"      Chabriat H, Joutel A, Dichgans M, et al. Cadasil. Lancet Neurol 2009; 8:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/4\">",
"      Weinmaster G. The ins and outs of notch signaling. Mol Cell Neurosci 1997; 9:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/5\">",
"      Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999; 284:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/6\">",
"      Domenga V, Fardoux P, Lacombe P, et al. Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. Genes Dev 2004; 18:2730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/7\">",
"      Joutel A, Andreux F, Gaulis S, et al. The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. J Clin Invest 2000; 105:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/8\">",
"      Wang W, Prince CZ, Mou Y, Pollman MJ. Notch3 signaling in vascular smooth muscle cells induces c-FLIP expression via ERK/MAPK activation. Resistance to Fas ligand-induced apoptosis. J Biol Chem 2002; 277:21723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/9\">",
"      Morrow D, Sweeney C, Birney YA, et al. Cyclic strain inhibits Notch receptor signaling in vascular smooth muscle cells in vitro. Circ Res 2005; 96:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/10\">",
"      Joutel A, Monet M, Domenga V, et al. Pathogenic mutations associated with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy differently affect Jagged1 binding and Notch3 activity via the RBP/JK signaling Pathway. Am J Hum Genet 2004; 74:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/11\">",
"      Duering M, Karpinska A, Rosner S, et al. Co-aggregate formation of CADASIL-mutant NOTCH3: a single-particle analysis. Hum Mol Genet 2011; 20:3256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/12\">",
"      Eikermann-Haerter K, Yuzawa I, Dilekoz E, et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy syndrome mutations increase susceptibility to spreading depression. Ann Neurol 2011; 69:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/13\">",
"      Lesnik Oberstein SA, van den Boom R, van Buchem MA, et al. Cerebral microbleeds in CADASIL. Neurology 2001; 57:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/14\">",
"      Joutel A, Chabriat H, Vahedi K, et al. Splice site mutation causing a seven amino acid Notch3 in-frame deletion in CADASIL. Neurology 2000; 54:1874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/15\">",
"      Arboleda-Velasquez JF, Lopera F, Lopez E, et al. C455R notch3 mutation in a Colombian CADASIL kindred with early onset of stroke. Neurology 2002; 59:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/16\">",
"      Monet-Lepr&ecirc;tre M, Bardot B, Lemaire B, et al. Distinct phenotypic and functional features of CADASIL mutations in the Notch3 ligand binding domain. Brain 2009; 132:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/17\">",
"      Miao Q, Paloneva T, Tuominen S, et al. Fibrosis and stenosis of the long penetrating cerebral arteries: the cause of the white matter pathology in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Brain Pathol 2004; 14:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/18\">",
"      Ruchoux MM, Maurage CA. CADASIL: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. J Neuropathol Exp Neurol 1997; 56:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/19\">",
"      Dichgans M, Wick M, Gasser T. Cerebrospinal fluid findings in CADASIL. Neurology 1999; 53:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/20\">",
"      Chabriat H, Pappata S, Ostergaard L, et al. Cerebral hemodynamics in CADASIL before and after acetazolamide challenge assessed with MRI bolus tracking. Stroke 2000; 31:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/21\">",
"      Pfefferkorn T, von Stuckrad-Barre S, Herzog J, et al. Reduced cerebrovascular CO(2) reactivity in CADASIL: A transcranial Doppler sonography study. Stroke 2001; 32:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/22\">",
"      Singhal S, Markus HS. Cerebrovascular reactivity and dynamic autoregulation in nondemented patients with CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy). J Neurol 2005; 252:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/23\">",
"      van den Boom R, Lesnik Oberstein SA, Spilt A, et al. Cerebral hemodynamics and white matter hyperintensities in CADASIL. J Cereb Blood Flow Metab 2003; 23:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/24\">",
"      Lacombe P, Oligo C, Domenga V, et al. Impaired cerebral vasoreactivity in a transgenic mouse model of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy arteriopathy. Stroke 2005; 36:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/25\">",
"      Dubroca C, Lacombe P, Domenga V, et al. Impaired vascular mechanotransduction in a transgenic mouse model of CADASIL arteriopathy. Stroke 2005; 36:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/26\">",
"      Joutel A, Monet-Lepr&ecirc;tre M, Gosele C, et al. Cerebrovascular dysfunction and microcirculation rarefaction precede white matter lesions in a mouse genetic model of cerebral ischemic small vessel disease. J Clin Invest 2010; 120:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/27\">",
"      Viswanathan A, Gray F, Bousser MG, et al. Cortical neuronal apoptosis in CADASIL. Stroke 2006; 37:2690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/28\">",
"      Razvi SS, Davidson R, Bone I, Muir KW. The prevalence of cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) in the west of Scotland. J Neurol Neurosurg Psychiatry 2005; 76:739.",
"     </a>",
"    </li>",
"    <li>",
"     Dichgans M. Klinische, bildgebende und genetische Untersuchungen bei CADASIL. Habilitationsschrift 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/30\">",
"      Narayan SK, Gorman G, Kalaria RN, et al. The minimum prevalence of CADASIL in northeast England. Neurology 2012; 78:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/31\">",
"      Dichgans M, Mayer M, Uttner I, et al. The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol 1998; 44:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/32\">",
"      Chabriat H, Vahedi K, Iba-Zizen MT, et al. Clinical spectrum of CADASIL: a study of 7 families. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Lancet 1995; 346:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/33\">",
"      Schon F, Martin RJ, Prevett M, et al. \"CADASIL coma\": an underdiagnosed acute encephalopathy. J Neurol Neurosurg Psychiatry 2003; 74:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/34\">",
"      Feuerhake F, Volk B, Ostertag CB, et al. Reversible coma with raised intracranial pressure: an unusual clinical manifestation of CADASIL. Acta Neuropathol 2002; 103:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/35\">",
"      Adib-Samii P, Brice G, Martin RJ, Markus HS. Clinical spectrum of CADASIL and the effect of cardiovascular risk factors on phenotype: study in 200 consecutively recruited individuals. Stroke 2010; 41:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/36\">",
"      Hutchinson M, O'Riordan J, Javed M, et al. Familial hemiplegic migraine and autosomal dominant arteriopathy with leukoencephalopathy (CADASIL). Ann Neurol 1995; 38:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/37\">",
"      Sourander P, W&aring;linder J. Hereditary multi-infarct dementia. Morphological and clinical studies of a new disease. Acta Neuropathol 1977; 39:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/38\">",
"      Guti&eacute;rrez-Molina M, Caminero Rodr&iacute;guez A, Mart&iacute;nez Garc&iacute;a C, et al. Small arterial granular degeneration in familial Binswanger's syndrome. Acta Neuropathol 1994; 87:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/39\">",
"      Maclean AV, Woods R, Alderson LM, et al. Spontaneous lobar haemorrhage in CADASIL. J Neurol Neurosurg Psychiatry 2005; 76:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/40\">",
"      Choi JC, Kang SY, Kang JH, Park JK. Intracerebral hemorrhages in CADASIL. Neurology 2006; 67:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/41\">",
"      Lesnik Oberstein SA, Jukema JW, Van Duinen SG, et al. Myocardial infarction in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Medicine (Baltimore) 2003; 82:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/42\">",
"      Cumurciuc R, Henry P, Gobron C, et al. Electrocardiogram in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy patients without any clinical evidence of coronary artery disease: a case-control study. Stroke 2006; 37:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/43\">",
"      Fattapposta F, Restuccia R, Pirro C, et al. Early diagnosis in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL): the role of MRI. Funct Neurol 2004; 19:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/44\">",
"      Coulthard A, Blank SC, Bushby K, et al. Distribution of cranial MRI abnormalities in patients with symptomatic and subclinical CADASIL. Br J Radiol 2000; 73:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/45\">",
"      Golomb MR, Sokol DK, Walsh LE, et al. Recurrent hemiplegia, normal MRI, and NOTCH3 mutation in a 14-year-old: is this early CADASIL? Neurology 2004; 62:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/46\">",
"      Granild-Jensen J, Jensen UB, Schwartz M, Hansen US. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy resulting in stroke in an 11-year-old male. Dev Med Child Neurol 2009; 51:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/47\">",
"      Hartley J, Westmacott R, Decker J, et al. Childhood-onset CADASIL: clinical, imaging, and neurocognitive features. J Child Neurol 2010; 25:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/48\">",
"      Liem MK, Oberstein SA, van der Grond J, et al. CADASIL and migraine: A narrative review. Cephalalgia 2010; 30:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/49\">",
"      Vahedi K, Chabriat H, Levy C, et al. Migraine with aura and brain magnetic resonance imaging abnormalities in patients with CADASIL. Arch Neurol 2004; 61:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/50\">",
"      Chabriat H, Tournier-Lasserve E, Vahedi K, et al. Autosomal dominant migraine with MRI white-matter abnormalities mapping to the CADASIL locus. Neurology 1995; 45:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/51\">",
"      Gunda B, Herv&eacute; D, Godin O, et al. Effects of gender on the phenotype of CADASIL. Stroke 2012; 43:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/52\">",
"      Rubio A, Rifkin D, Powers JM, et al. Phenotypic variability of CADASIL and novel morphologic findings. Acta Neuropathol 1997; 94:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/53\">",
"      Choi EJ, Choi CG, Kim JS. Large cerebral artery involvement in CADASIL. Neurology 2005; 65:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/54\">",
"      Viswanathan A, Gschwendtner A, Guichard JP, et al. Lacunar lesions are independently associated with disability and cognitive impairment in CADASIL. Neurology 2007; 69:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/55\">",
"      Peters N, Holtmannsp&ouml;tter M, Opherk C, et al. Brain volume changes in CADASIL: a serial MRI study in pure subcortical ischemic vascular disease. Neurology 2006; 66:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/56\">",
"      Duering M, Zieren N, Herv&eacute; D, et al. Strategic role of frontal white matter tracts in vascular cognitive impairment: a voxel-based lesion-symptom mapping study in CADASIL. Brain 2011; 134:2366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/57\">",
"      Dichgans M. Cognition in CADASIL. Stroke 2009; 40:S45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/58\">",
"      Amberla K, W&auml;ljas M, Tuominen S, et al. Insidious cognitive decline in CADASIL. Stroke 2004; 35:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/59\">",
"      Buffon F, Porcher R, Hernandez K, et al. Cognitive profile in CADASIL. J Neurol Neurosurg Psychiatry 2006; 77:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/60\">",
"      Peters N, Herzog J, Opherk C, Dichgans M. A two-year clinical follow-up study in 80 CADASIL subjects: progression patterns and implications for clinical trials. Stroke 2004; 35:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/61\">",
"      Peters N, Opherk C, Danek A, et al. The pattern of cognitive performance in CADASIL: a monogenic condition leading to subcortical ischemic vascular dementia. Am J Psychiatry 2005; 162:2078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/62\">",
"      Valenti R, Poggesi A, Pescini F, et al. Psychiatric disturbances in CADASIL: a brief review. Acta Neurol Scand 2008; 118:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/63\">",
"      L&aring;gas PA, Juvonen V. Schizophrenia in a patient with cerebral autosomally dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL disease). Nord J Psychiatry 2001; 55:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/64\">",
"      Reyes S, Viswanathan A, Godin O, et al. Apathy: a major symptom in CADASIL. Neurology 2009; 72:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/65\">",
"      Roine S, P&ouml;yh&ouml;nen M, Timonen S, et al. Neurologic symptoms are common during gestation and puerperium in CADASIL. Neurology 2005; 64:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/66\">",
"      Chabriat H, Levy C, Taillia H, et al. Patterns of MRI lesions in CADASIL. Neurology 1998; 51:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/67\">",
"      Auer DP, P&uuml;tz B, G&ouml;ssl C, et al. Differential lesion patterns in CADASIL and sporadic subcortical arteriosclerotic encephalopathy: MR imaging study with statistical parametric group comparison. Radiology 2001; 218:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/68\">",
"      Dichgans M, Filippi M, Br&uuml;ning R, et al. Quantitative MRI in CADASIL: correlation with disability and cognitive performance. Neurology 1999; 52:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/69\">",
"      Liem MK, Lesnik Oberstein SA, Haan J, et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: progression of MR abnormalities in prospective 7-year follow-up study. Radiology 2008; 249:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/70\">",
"      O'Sullivan M, Jarosz JM, Martin RJ, et al. MRI hyperintensities of the temporal lobe and external capsule in patients with CADASIL. Neurology 2001; 56:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/71\">",
"      van den Boom R, Lesnik Oberstein SA, Ferrari MD, et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: MR imaging findings at different ages--3rd-6th decades. Radiology 2003; 229:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/72\">",
"      van Den Boom R, Lesnik Oberstein SA, van Duinen SG, et al. Subcortical lacunar lesions: an MR imaging finding in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Radiology 2002; 224:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/73\">",
"      Dichgans M, Holtmannsp&ouml;tter M, Herzog J, et al. Cerebral microbleeds in CADASIL: a gradient-echo magnetic resonance imaging and autopsy study. Stroke 2002; 33:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/74\">",
"      Viswanathan A, Guichard JP, Gschwendtner A, et al. Blood pressure and haemoglobin A1c are associated with microhaemorrhage in CADASIL: a two-centre cohort study. Brain 2006; 129:2375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/75\">",
"      Duering M, Righart R, Csanadi E, et al. Incident subcortical infarcts induce focal thinning in connected cortical regions. Neurology 2012; 79:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/76\">",
"      Holtmannsp&ouml;tter M, Peters N, Opherk C, et al. Diffusion magnetic resonance histograms as a surrogate marker and predictor of disease progression in CADASIL: a two-year follow-up study. Stroke 2005; 36:2559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/77\">",
"      Dichgans M, Petersen D. Angiographic complications in CADASIL. Lancet 1997; 349:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/78\">",
"      Tatsch K, Koch W, Linke R, et al. Cortical hypometabolism and crossed cerebellar diaschisis suggest subcortically induced disconnection in CADASIL: an 18F-FDG PET study. J Nucl Med 2003; 44:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/79\">",
"      Tuominen S, Miao Q, Kurki T, et al. Positron emission tomography examination of cerebral blood flow and glucose metabolism in young CADASIL patients. Stroke 2004; 35:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/80\">",
"      Jouvent E, Poupon C, Gray F, et al. Intracortical infarcts in small vessel disease: a combined 7-T postmortem MRI and neuropathological case study in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Stroke 2011; 42:e27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/81\">",
"      Pescini F, Nannucci S, Bertaccini B, et al. The Cerebral Autosomal-Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Scale: a screening tool to select patients for NOTCH3 gene analysis. Stroke 2012; 43:2871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/82\">",
"      Peters N, Opherk C, Bergmann T, et al. Spectrum of mutations in biopsy-proven CADASIL: implications for diagnostic strategies. Arch Neurol 2005; 62:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/83\">",
"      Joutel A, Vahedi K, Corpechot C, et al. Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet 1997; 350:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/84\">",
"      Mazzei R, Conforti FL, Lanza PL, et al. A novel Notch3 gene mutation not involving a cysteine residue in an Italian family with CADASIL. Neurology 2004; 63:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/85\">",
"      Ruchoux MM, Chabriat H, Bousser MG, et al. Presence of ultrastructural arterial lesions in muscle and skin vessels of patients with CADASIL. Stroke 1994; 25:2291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/86\">",
"      Mayer M, Straube A, Bruening R, et al. Muscle and skin biopsies are a sensitive diagnostic tool in the diagnosis of CADASIL. J Neurol 1999; 246:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/87\">",
"      Ebke M, Dichgans M, Bergmann M, et al. CADASIL: skin biopsy allows diagnosis in early stages. Acta Neurol Scand 1997; 95:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/88\">",
"      Joutel A, Favrole P, Labauge P, et al. Skin biopsy immunostaining with a Notch3 monoclonal antibody for CADASIL diagnosis. Lancet 2001; 358:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/89\">",
"      Lesnik Oberstein SA, van Duinen SG, van den Boom R, et al. Evaluation of diagnostic NOTCH3 immunostaining in CADASIL. Acta Neuropathol 2003; 106:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/90\">",
"      Wang Q, Yan J, Chen X, et al. Statins: multiple neuroprotective mechanisms in neurodegenerative diseases. Exp Neurol 2011; 230:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/91\">",
"      Iannaccone S, Ferini-Strambi L. Pharmacologic treatment of emotional lability. Clin Neuropharmacol 1996; 19:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/92\">",
"      Weller M, Dichgans J, Klockgether T. Acetazolamide-responsive migraine in CADASIL. Neurology 1998; 50:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/93\">",
"      Forteza AM, Brozman B, Rabinstein AA, et al. Acetazolamide for the treatment of migraine with aura in CADASIL. Neurology 2001; 57:2144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/94\">",
"      International Huntington Association and the World Federation of Neurology Research Group on Huntington's Chorea. Guidelines for the molecular genetics predictive test in Huntington's disease. J Med Genet 1994; 31:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/16/11530/abstract/95\">",
"      Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. American Society of Human Genetics Board of Directors, American College of Medical Genetics Board of Directors. Am J Hum Genet 1995; 57:1233.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1091 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-FE8AB3007C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_16_11530=[""].join("\n");
var outline_f11_16_11530=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Molecular mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Genotype-phenotype correlations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hemodynamic changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Age at onset",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Migraine with aura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Ischemic stroke and TIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cognitive deficits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Neuropsychiatric symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CADASIL and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      NEUROIMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Temporal lobe and external capsule hyperintensities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Subcortical lacunar lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Cerebral microbleeds",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Brain atrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Genetic screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Skin biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Ischemic manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Symptomatic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Screening asymptomatic family members",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1091\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1091|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/59/39859\" title=\"diagnostic image 1\">",
"      FLAIR MRI CADASIL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/36/30278\" title=\"diagnostic image 2\">",
"      Anterior temporal lobe CADASIL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21194?source=related_link\">",
"      Acute treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17305?source=related_link\">",
"      Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=related_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17000?source=related_link\">",
"      Diagnosis and treatment of oropharyngeal dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10426?source=related_link\">",
"      Initial evaluation and management of transient ischemic attack and minor stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4026?source=related_link\">",
"      Lacunar infarcts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=related_link\">",
"      Management of persistent hyperglycemia in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=related_link\">",
"      Preventive treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=related_link\">",
"      Treatment of urinary incontinence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_16_11531="Infant AZT dosing recommendations";
var content_f11_16_11531=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Simplified infant zidovudine dosing recommendations*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Infant age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Zidovudine&nbsp;daily dosing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Birth to 6 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Birth weight 2000-2499 g",
"       </td>",
"       <td>",
"        10 mg twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Birth weight &gt;2500 g",
"       </td>",
"       <td>",
"        15 mg twice daily",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Low birth weight infants should receive mg/kg dosing.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access: Recommendations for a public health approach (2010 version). World Health Organization, Geneva 2010. Copyright &copy; 2010 WHO. Available from:",
"     <a href=\"file://whqlibdoc.who.int/publications/2010/9789241599818_eng.pdf\">",
"      file://whqlibdoc.who.int/publications/2010/9789241599818_eng.pdf",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_16_11531=[""].join("\n");
var outline_f11_16_11531=null;
var title_f11_16_11532="Diuretic herbal ingredients";
var content_f11_16_11532=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F82127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F82127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diuretic herbal ingredients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Agrimony",
"       </td>",
"       <td>",
"        Activity in vivo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Artichoke",
"       </td>",
"       <td>",
"        Reputed action",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Boldo",
"       </td>",
"       <td>",
"        Irritant oil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Broom",
"       </td>",
"       <td>",
"        Reputed action",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Buchu",
"       </td>",
"       <td>",
"        Reputed action",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Burdock",
"       </td>",
"       <td>",
"        Reputed action",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Celery",
"       </td>",
"       <td>",
"        Reputed action",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cornsilk",
"       </td>",
"       <td>",
"        Human activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Couchgrass",
"       </td>",
"       <td>",
"        Activity in vivo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dandelion",
"       </td>",
"       <td>",
"        Activity in vivo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elder",
"       </td>",
"       <td>",
"        Activity in vivo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Guaiacum",
"       </td>",
"       <td>",
"        Reputed action",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Juniper",
"       </td>",
"       <td>",
"        Reputed action; terpinen-4-ol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pokeroot",
"       </td>",
"       <td>",
"        Activity in vivo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shepherd's purse",
"       </td>",
"       <td>",
"        Activity in vivo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Squill",
"       </td>",
"       <td>",
"        Activity in vivo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uva Ursi",
"       </td>",
"       <td>",
"        Reputed action",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yarrow",
"       </td>",
"       <td>",
"        Activity in vivo",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals. The Pharmaceutical Press 1996, p. 277.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_16_11532=[""].join("\n");
var outline_f11_16_11532=null;
var title_f11_16_11533="Causes of diarrhea in AIDS";
var content_f11_16_11533=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58409&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58409&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of diarrhea in patients with AIDS",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Protozoal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Microsporidium*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cryptosporidium*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Isospora belli",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Giardia lamblia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Entamoeba histolytica",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Leishmania donovani",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Blastocystis hominis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cyclospora sp",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Viral",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cytomegalovirus*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Herpes simplex",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Adenovirus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rotavirus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Norwalk",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            HIV",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Gut neoplasms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lymphoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Kaposi's sarcoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Pancreatic insufficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Infectious pancreatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cytomegalovirus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Mycobacterium avium complex",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Drug-induced pancreatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Didanosine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pentamidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Tumor invasion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Lymphoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Kaposi's sarcoma",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Bacterial",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Salmonella*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Campylobacter*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mycobacterium avium complex",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mycobacterium tuberculosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Clostridium difficile",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Shigella",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Small bowel bacterial overgrowth",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vibrio sp",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Fungal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Histoplasmosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Coccidiomycosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Candida albicans",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Idiopathic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            \"AIDS enteropathy\"",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * More frequent.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_16_11533=[""].join("\n");
var outline_f11_16_11533=null;
var title_f11_16_11534="Duration of labor by dilation at admission";
var content_f11_16_11534=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Duration of labor by dilation at admission",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 330px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The 95th percentiles of cumulative duration of labor from admission among singleton term nulliparous women with spontaneous onset of labor, vaginal delivery, and normal neonatal outcomes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Zhang J, Landy H, Ware Branch D, et al. Contemporary patterns of spontaneous labor with normal neonatal outcomes. Obstet Gynecol 2010; 116:1281. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_16_11534=[""].join("\n");
var outline_f11_16_11534=null;
var title_f11_16_11535="Contents: Screening preventive medicine";
var content_f11_16_11535=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Screening preventive medicine",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Screening preventive medicine",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Cardiovascular disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/36/585\">",
"           Antimicrobial prophylaxis for bacterial endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/12/37066\">",
"           Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/28/1482\">",
"           Cardiovascular risk of smoking and benefits of smoking cessation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/50/19240\">",
"           Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/44/30410\">",
"           Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/28/14793\">",
"           Exercise and fitness in the prevention of cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/35/3641\">",
"           Obesity, weight reduction, and cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/28/5576\">",
"           Overview of primary prevention of coronary heart disease and stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/58/24488\">",
"           Screening for abdominal aortic aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/35/34361\">",
"           Screening for asymptomatic carotid artery stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/12/20679\">",
"           Screening for asymptomatic left ventricular dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/54/34665\">",
"           Screening for cardiovascular risk with C-reactive protein",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/50/26409\">",
"           Screening for coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/20/18761\">",
"           Screening for coronary heart disease in patients with diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/26/20903\">",
"           Screening for inherited thrombophilia in asymptomatic populations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/43/3767\">",
"           Screening for intracranial aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/40/24200\">",
"           Screening for lower extremity peripheral artery disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/29/33241\">",
"           Screening guidelines for dyslipidemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/37/31318\">",
"           Screening to prevent sudden cardiac death in athletes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/60/40906\">",
"           Secondary prevention of cardiovascular disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General screening and prevention",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/62/23529\">",
"           Aspirin in the primary prevention of cardiovascular disease and cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/46/34537\">",
"           Evidence-based approach to prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/59/15289\">",
"           Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/4/37962\">",
"           Overview of preventive medicine in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/3/23609\">",
"           Overview of smoking cessation management in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/13/17626\">",
"           Pharmacotherapy for smoking cessation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/41/20120\">",
"           Primary care of gay men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/17/21785\">",
"           Radiation-related risks of imaging studies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/38/28261\">",
"           Screening for testicular cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infectious disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/36/585\">",
"           Antimicrobial prophylaxis for bacterial endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/44/41670\">",
"           Approach to immunizations in healthy adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/38/1641\">",
"           Hepatitis A virus vaccination and postexposure prophylaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/60/31690\">",
"           Hepatitis B virus vaccination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/0/13322\">",
"           Immunizations for healthcare providers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/21/2394\">",
"           Immunizations for travel",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/25/37273\">",
"           Immunizations in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/50/11047\">",
"           Pneumococcal immunization in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/12/21705\">",
"           Pneumococcal vaccination in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/55/3960\">",
"           Prevention of Lyme disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/3/13370\">",
"           Prevention of malaria infection in travelers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/13/8408\">",
"           Screening for Chlamydia trachomatis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/8/37002\">",
"           Seasonal influenza vaccination in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/54/7014\">",
"           Tetanus-diphtheria toxoid vaccination in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/48/8967\">",
"           Travel advice",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Metabolic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/7/26744\">",
"           Diagnosis of and screening for hypothyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/16/2312\">",
"           Screening for diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/15/12535\">",
"           Screening for hereditary hemochromatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/28/40393\">",
"           Screening for osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/32/18952\">",
"           Treatment of hereditary hemochromatosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neoplastic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/35/39482\">",
"           Breast imaging: Mammography and ultrasonography",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/24/42378\">",
"           Cancer prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/3/8248\">",
"           Cervical cancer screening tests: Evidence of effectiveness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/32/35337\">",
"           Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/14/16618\">",
"           Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/31/32249\">",
"           Genetic testing for hereditary breast and ovarian cancer syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/5/29783\">",
"           Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/0/17418\">",
"           Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/2/41001\">",
"           Measurement of prostate specific antigen",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/9/3224\">",
"           Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/41/18073\">",
"           Primary prevention of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/52/31562\">",
"           Risk factors for prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/51/2872\">",
"           Risk prediction models for breast cancer screening",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/16/16650\">",
"           Screening and early detection of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/52/6983\">",
"           Screening and prevention of gastric cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/49/41754\">",
"           Screening for breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/16/38154\">",
"           Screening for cervical cancer: Rationale and recommendations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/10/37034\">",
"           Screening for colorectal cancer: Strategies in patients at average risk",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/41/9881\">",
"           Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/58/28586\">",
"           Screening for lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/14/10474\">",
"           Screening for ovarian cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/8/42122\">",
"           Screening for prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/9/38042\">",
"           Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-366F64DD28-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f11_16_11535=[""].join("\n");
var outline_f11_16_11535=null;
